C. M. Acevedo-henao, G. Valette, P. Miglierini, E. Lefur, and O. Pradier, Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity, Cancer Radiother. J. Soc. Francaise Radiother. Oncol, vol.16, pp.601-603, 2012.

D. J. Adelstein, L. A. Kalish, G. L. Adams, H. Wagner, M. M. Oken et al., Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.11, pp.2136-2142, 1993.

L. Ai, K. K. Stephenson, W. Ling, C. Zuo, P. Mukunyadzi et al.,

, The p16 (CDKN2a/INK4a) Tumor-Suppressor Gene in Head and Neck Squamous Cell Carcinoma: A Promoter Methylation and Protein Expression Study in 100 Cases, Mod. Pathol, vol.16, pp.944-950

J. Albanell, J. Codony, A. Rovira, B. Mellado, and P. Gascón, Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4, Adv. Exp. Med. Biol, vol.532, pp.253-268, 2003.

D. Albo, D. H. Berger, T. N. Wang, X. Hu, V. Rothman et al., , 1997.

J. Albrengues, G. Meneguzzi, and C. Gaggioli, Analysis of Collective Invasion of Carcinoma Cells in a 3D Organotypic Model, Molecular Dermatology: Methods and Protocols, C. Has, and C, 2013.

. Sitaru, , pp.243-252

J. Albrengues, I. Bourget, C. Pons, V. Butet, P. Hofman et al., LIF mediates proinvasive activation of stromal fibroblasts in cancer, Cell Rep, vol.7, pp.1664-1678, 2014.

J. Albrengues, T. Bertero, E. Grasset, S. Bonan, M. Maiel et al., Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts, Nat. Commun, vol.6, p.10204, 2015.

N. R. Alexander, N. L. Tran, H. Rekapally, C. E. Summers, C. Glackin et al., Ncadherin Gene Expression in Prostate Carcinoma Is Modulated by Integrin-Dependent Nuclear Translocation of Twist1, Cancer Res, vol.66, pp.3365-3369, 2006.

M. P. Allen, M. Xu, D. A. Linseman, J. E. Pawlowski, G. M. Bokoch et al., Adhesion-related Kinase Repression of Gonadotropin-releasing Hormone Gene Expression Requires Rac Activation of the Extracellular Signal-regulated Kinase Pathway, J. Biol. Chem, vol.277, pp.38133-38140, 2002.

S. Ammoun, L. Provenzano, L. Zhou, M. Barczyk, K. Evans et al., Axl/Gas6/NF?B signalling in schwannoma pathological proliferation, adhesion and survival, Oncogene, vol.33, pp.336-346, 2014.

K. K. Ang, Q. Zhang, D. I. Rosenthal, P. F. Nguyen-tan, E. J. Sherman et al., and neck carcinoma: RTOG 0522, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.32, pp.2940-2950, 2014.

K. K. Ang, B. A. Berkey, X. Tu, H. Zhang, R. Katz et al., Impact of Epidermal Growth Factor Receptor Expression on Survival and Pattern of Relapse in Patients with Advanced Head and Neck Carcinoma, vol.8

M. Bartoschek, N. Oskolkov, M. Bocci, J. Lövrot, C. Larsson et al., Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing, Nat. Commun, vol.9, p.5150, 2018.

J. Baselga, The EGFR as a target for anticancer therapy--focus on cetuximab, Eur. J. Cancer Oxf. Engl, vol.37, pp.16-22, 1990.

J. Baum and H. S. Duffy, Fibroblasts and Myofibroblasts: What are we talking about?, J. Cardiovasc. Pharmacol, vol.57, pp.376-379, 2011.

V. Bazan, I. Zanna, M. Migliavacca, M. T. Sanz-casla, M. L. Maestro et al., Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma, J. Cell. Physiol, vol.192, pp.286-293, 2002.

L. A. Bazley and W. J. Gullick, The epidermal growth factor receptor family, Endocr. Relat. Cancer, vol.12, issue.1, pp.17-27, 2005.

A. C. Bellail, J. J. Olson, X. Yang, Z. J. Chen, and C. Hao, , 2012.

A. Benedicto, I. Romayor, A. , and B. , Role of liver ICAM-1 in metastasis, Oncol. Lett, vol.14, pp.3883-3892, 2017.

Y. Ben-neriah, K. , and M. , Inflammation meets cancer, with NF-?B as the matchmaker, Nat. Immunol, vol.12, pp.715-723, 2011.

K. Bensaad and K. H. Vousden, p53: new roles in metabolism, vol.17, pp.286-291, 2007.

G. Bergers and L. E. Benjamin, Tumorigenesis and the angiogenic switch, Nat. Rev. Cancer, vol.3, pp.401-410, 2003.

J. Berlin, M. Neubauer, P. Swanson, W. G. Harker, H. Burris et al., , 2006.

, Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ? 10% epidermal growth factor receptor (EGFr), J. Clin. Oncol, vol.24, pp.3548-3548

J. Bernier and J. S. Cooper, Chemoradiation after Surgery for High-Risk Head and Neck Cancer Patients: How Strong Is the Evidence?, The Oncologist, vol.10, pp.215-224, 2005.

J. Bernier, C. Domenge, M. Ozsahin, K. Matuszewska, J. Lefèbvre et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer, N. Engl. J. Med, vol.350, pp.1945-1952, 2004.

T. Bertero, W. M. Oldham, E. M. Grasset, I. Bourget, E. Boulter et al., Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy, Cell Metab, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01998873

R. Beyaert, K. Heyninck, and S. Van-huffel, A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis, Biochem. Pharmacol, vol.60, pp.1143-1151, 2000.

M. Beyzadeoglu, G. Ozyigit, and U. Selek, Radiation Therapy for Head and Neck Cancers: A Case-Based Review, 2014.

N. A. Bhowmick, E. G. Neilson, and H. L. Moses, Stromal fibroblasts in cancer initiation and progression, Nature, vol.432, pp.332-337, 2004.

C. Birchmeier, W. Birchmeier, E. Gherardi, and G. F. Vande-woude, Met, metastasis, motility and more, Nat. Rev. Mol. Cell Biol, vol.4, pp.915-925, 2003.

J. S. Biscardi, M. C. Maa, D. A. Tice, M. E. Cox, T. H. Leu et al., c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function, J. Biol. Chem, vol.274, pp.8335-8343, 1999.

M. J. Bissell, H. G. Hall, and G. Parry, How does the extracellular matrix direct gene expression?, J. Theor. Biol, vol.99, pp.31-68, 1982.

W. J. Blot, J. K. Mclaughlin, D. M. Winn, D. F. Austin, R. S. Greenberg et al., Smoking and drinking in relation to oral and pharyngeal cancer, Cancer Res, vol.48, pp.3282-3287, 1988.

S. Bonan, J. Albrengues, E. Grasset, S. Kuzet, N. Nottet et al., Membrane-bound ICAM-1 contributes to the onset of proinvasive tumor stroma by controlling acto-myosin contractility in carcinoma-associated fibroblasts, Oncotarget, vol.8, pp.1304-1320, 2016.

A. Bondareva, C. M. Downey, F. Ayres, W. Liu, S. K. Boyd et al., , 2009.

, The Lysyl Oxidase Inhibitor, ?-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells, PLOS ONE, vol.4, p.5620

J. A. Bonner, N. J. Maihle, B. R. Folven, T. J. Christianson, and K. Spain, Int. J. Radiat. Oncol. ? Biol. ? Phys, vol.29, pp.243-247, 1994.

J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin et al., Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med, vol.354, pp.567-578, 2006.

J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N. Engl. J. Med, vol.354, pp.567-578, 2006.

J. A. Bonner, P. M. Harari, J. Giralt, R. B. Cohen, C. U. Jones et al., Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximabinduced rash and survival, Lancet Oncol, vol.11, pp.21-28, 2010.

L. A. Borthwick, T. A. Wynn, and A. J. Fisher, Cytokine mediated tissue fibrosis, Biochim. Biophys. Acta, vol.1832, pp.1049-1060, 2013.

R. J. Bova, D. I. Quinn, J. S. Nankervis, I. E. Cole, B. F. Sheridan et al., Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.5, pp.2810-2819, 1999.

B. Boyer, A. M. Vallés, and N. Edme, Induction and regulation of epithelial-mesenchymal transitions, Biochem. Pharmacol, vol.60, pp.1091-1099, 2000.

T. Brabletz, R. Kalluri, M. A. Nieto, and R. A. Weinberg, EMT in cancer, Nat. Rev. Cancer, vol.18, pp.128-134, 2018.

T. M. Brand, M. Iida, A. P. Stein, K. L. Corrigan, C. M. Braverman et al., AXL mediates resistance to cetuximab therapy, Cancer Res, vol.74, pp.5152-5164, 2014.

T. M. Brand, M. Iida, A. P. Stein, K. L. Corrigan, C. M. Braverman et al., AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.21, pp.2601-2612, 2015.

J. Braunger, L. Schleithoff, A. S. Schulz, H. Kessler, R. Lammers et al., Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site, Oncogene, vol.14, pp.2619-2631, 1997.

M. Bredel, C. Bredel, D. Juric, G. Duran, R. X. Yu et al., TNFAIP3/A20 as a potential regulator of NF-?B-mediated resistance to O6-alkylating chemotherapy in glioblastoma multiforme, Cancer Res, vol.66, pp.1054-1054, 2006.

R. M. Bremnes, T. Dønnem, S. Al-saad, K. Al-shibli, S. Andersen et al., The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer, J. Thorac. Oncol. Off. Publ. Int, 2011.

, Assoc. Study Lung Cancer, vol.6, pp.209-217

A. Brichkina, T. Bertero, H. M. Loh, N. T. Nguyen, A. Emelyanov et al., p38MAPK builds a hyaluronan cancer niche to drive lung tumorigenesis, vol.30, pp.2623-2636, 2016.

D. M. Brizel, M. E. Albers, S. R. Fisher, R. L. Scher, W. J. Richtsmeier et al., Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer, N. Engl. J. Med, vol.338, pp.1798-1804, 1998.

J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell et al., Stat3 as an Oncogene, vol.98, pp.295-303, 1999.

D. A. Bronzert, P. Pantazis, H. N. Antoniades, A. Kasid, N. Davidson et al., Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines, Proc. Natl. Acad. Sci. U. S. A, vol.84, pp.5763-5767, 1987.

M. Buehler, B. Tse, A. Leboucq, F. Jacob, R. Caduff et al., Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer, BioMed Res. Int, p.238284, 2013.

A. W. Burgess, H. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett et al., An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors, Mol. Cell, vol.12, pp.541-552, 2003.

B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, A. A. Forastiere et al., neck cancer: an Eastern Cooperative Oncology Group study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.23, pp.8646-8654, 2005.

F. Bussolino, M. F. Di-renzo, M. Ziche, E. Bocchietto, M. Olivero et al., Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth, J. Cell Biol, vol.119, pp.629-641, 1992.

D. T. Butcher, T. Alliston, and V. M. Weaver, A tense situation: forcing tumour progression, 2009.

, Nat. Rev. Cancer, vol.9, pp.108-122

M. Chatzinikolaidou, Cell spheroids: the new frontiers in in vitro models for cancer drug validation, Drug Discov. Today, vol.21, pp.1553-1560, 2016.

N. I. Chaudhary, G. J. Roth, F. Hilberg, J. Müller-quernheim, A. Prasse et al., Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis, Eur. Respir. J, vol.29, pp.976-985, 2007.

B. Chen, Y. Ni, J. Liu, Y. Zhang, Y. et al., Bone Marrow-Derived Mesenchymal Stem Cells Exert Diverse Effects on Different Macrophage Subsets, Stem Cells Int, 2018.

P. Chen, Q. Li, Y. , and Z. , Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma, Ann. Diagn. Pathol, vol.17, pp.425-429, 2013.

S. Chen, H. Xing, S. Li, J. Yu, H. Li et al., , 2015.

, Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells, Leuk. Res, vol.39, pp.976-983

V. M. Chen, R. Shelke, A. Nyström, N. Laver, J. F. Sampson et al.,

G. Z. Cheng, J. Chan, Q. Wang, W. Zhang, C. D. Sun et al., Twist Transcriptionally Up-regulates AKT2 in Breast Cancer Cells Leading to Increased Migration, Invasion, and Resistance to Paclitaxel, Cancer Res, vol.67, pp.1979-1987, 2007.

R. J. Cho, L. B. Alexandrov, N. Y. Den-breems, V. S. Atanasova, M. Farshchian et al., APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa, Sci. Transl. Med, vol.10, 2018.

C. R. Chong and P. A. Jänne, The quest to overcome resistance to EGFR-targeted therapies in cancer, Nat. Med, vol.19, pp.1389-1400, 2013.

N. Choong and E. Vokes, Expanding role of the medical oncologist in the management of head and neck cancer, CA. Cancer J. Clin, vol.58, pp.32-53, 2008.

C. Chothia and E. Y. Jones, The Molecular Structure of Cell Adhesion Molecules, Annu. Rev. Biochem, vol.66, pp.823-862, 1997.

J. J. Christiansen and A. K. Rajasekaran, Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis, Cancer Res, vol.66, pp.8319-8326, 2006.

C. H. Chung, J. S. Parker, G. Karaca, J. Wu, W. K. Funkhouser et al., Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression, Cancer Cell, vol.5, pp.489-500, 2004.

C. H. Chung, J. S. Parker, K. Ely, J. Carter, Y. Yi et al., Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-?B Signaling as Characteristics of a Highrisk Head and Neck Squamous Cell Carcinoma, Cancer Res, vol.66, pp.8210-8218, 2006.

F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico et al., Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.6, pp.2053-2063, 2000.

P. Cirri and P. Chiarugi, Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression, Cancer Metastasis Rev, vol.31, pp.195-208, 2012.

A. Citri, K. B. Skaria, Y. , and Y. , The deaf and the dumb: the biology of ErbB-2 and ErbB, 2003.

, Exp. Cell Res, vol.284, pp.54-65

A. Clapéron, M. Mergey, T. H. Nguyen-ho-bouldoires, D. Vignjevic, D. Wendum et al., , 2014.

J. R. Clark and E. Frei, Chemotherapy for head and neck cancer: progress and controversy in the management of patients with M0 disease, Semin. Oncol, vol.16, pp.44-57, 1989.

E. A. Clark, W. G. King, J. S. Brugge, M. Symons, and R. O. Hynes, Integrin-mediated Signals Regulated by Members of the Rho Family of GTPases, J. Cell Biol, vol.142, pp.573-586, 1998.

J. Cloos, M. R. Spitz, S. P. Schantz, T. C. Hsu, Z. F. Zhang et al., Genetic susceptibility to head and neck squamous cell carcinoma, J. Natl. Cancer Inst, vol.88, pp.530-535, 1996.

J. D. Codd, J. R. Salisbury, G. Packham, and L. J. Nicholson, , 1999.

D. M. Cognetti, R. S. Weber, and S. Y. Lai, Head and Neck Cancer: An Evolving Treatment Paradigm, Cancer, vol.113, pp.1911-1932, 2008.

S. Cohen, Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal, J. Biol. Chem, vol.237, pp.1555-1562, 1962.

S. Cohen and G. Carpenter, Human epidermal growth factor: isolation and chemical and biological properties, Proc. Natl. Acad. Sci. U. S. A, vol.72, pp.1317-1321, 1975.

K. Collins, T. Jacks, and N. P. Pavletich, The cell cycle and cancer, Proc. Natl. Acad. Sci. U, 1997.

S. , , vol.94, pp.2776-2778

J. Condeelis and J. W. Pollard, Macrophages: obligate partners for tumor cell migration, invasion, and metastasis, Cell, vol.124, pp.263-266, 2006.

M. W. Conklin, J. C. Eickhoff, K. M. Riching, C. A. Pehlke, K. W. Eliceiri et al., Aligned collagen is a prognostic signature for survival in human breast carcinoma, Am. J. Pathol, vol.178, pp.1221-1232, 2011.

J. S. Cooper, T. F. Pajak, A. A. Forastiere, J. Jacobs, B. H. Campbell et al., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck, N. Engl. J. Med, vol.350, pp.1937-1944, 2004.

B. Coornaert, I. Carpentier, and R. Beyaert, A20: Central Gatekeeper in Inflammation and Immunity, J. Biol. Chem, vol.284, pp.8217-8221, 2009.

M. Cordenonsi, F. Zanconato, L. Azzolin, M. Forcato, A. Rosato et al., The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on, Breast Cancer Cells. Cell, vol.147, pp.759-772, 2011.

A. Costa, A. Scholer-dahirel, and F. Mechta-grigoriou, The role of reactive oxygen species and metabolism on cancer cells and their microenvironment, Semin. Cancer Biol, vol.25, pp.23-32, 2014.

D. B. Costa, B. Halmos, A. Kumar, S. T. Schumer, M. S. Huberman et al., BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations, PLOS Med, vol.4, p.315, 2007.

B. Costa-silva, N. M. Aiello, A. J. Ocean, S. Singh, H. Zhang et al., Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver, Nat. Cell Biol, vol.17, pp.816-826, 2015.

T. R. Cox and J. T. Erler, Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer, Dis. Model. Mech, vol.4, pp.165-178, 2011.

T. R. Cox, D. Bird, A. Baker, H. E. Barker, M. W. Ho et al., LOXmediated collagen crosslinking is responsible for fibrosis-enhanced metastasis, Cancer Res, vol.73, pp.1721-1732, 2013.

M. S. Cragg, J. Kuroda, H. Puthalakath, D. C. Huang, and A. Strasser, Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3, 2007.

. Mimetics, PLOS Med, vol.4, p.316

Y. Crawford and N. Ferrara, VEGF inhibition: insights from preclinical and clinical studies, Cell Tissue Res, vol.335, pp.261-269, 2009.

E. T. Creagan, K. S. Fountain, S. Frytak, L. W. Desanto, and J. D. Earle, Concomitant radiation therapy and cis-diamminedichloroplatinum (II) in patients with advanced head and neck cancer, Med. Pediatr. Oncol, vol.9, pp.119-120, 1981.

H. Creedon, L. Gómez-cuadrado, ?. Tarnauskait?, J. Balla, M. Canel et al., Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy, Oncotarget, vol.7, pp.11539-11552, 2016.

L. C. Crowley and N. J. Waterhouse, Detecting Cleaved Caspase-3 in Apoptotic Cells by Flow Cytometry, Cold Spring Harb. Protoc, 2016.

D. G. Danahey, E. J. Tobin, D. E. Schuller, C. M. Bier-laning, C. M. Weghorst et al., , 1999.

I. Darby, O. Skalli, and G. Gabbiani, Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing, Lab. Investig. J. Tech. Methods Pathol, vol.63, pp.21-29, 1990.

I. A. Darby, B. Laverdet, F. Bonté, and A. Desmoulière, Fibroblasts and myofibroblasts in wound healing, Clin. Cosmet. Investig. Dermatol, vol.7, pp.301-311, 2014.

V. R. Dasari, V. Mazack, W. Feng, J. Nash, D. J. Carey et al., Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells, Oncotarget, vol.8, pp.28628-28640, 2017.

H. Daub, F. U. Weiss, C. Wallasch, and A. Ullrich, Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors, Nature, vol.379, pp.557-560, 1996.

J. M. David and A. K. Rajasekaran, Dishonorable discharge: the oncogenic roles of cleaved Ecadherin fragments, Cancer Res, vol.72, pp.2917-2923, 2012.

P. J. Day, A. Cleasby, I. J. Tickle, M. O'reilly, J. E. Coyle et al., Crystal structure of human CDK4 in complex with a D-type cyclin, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.4166-4170, 2009.

D. Wever, O. Nguyen, Q. Van-hoorde, L. Bracke, M. Bruyneel et al.,

-. Tenascin and S. F. Hgf, produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol, vol.18, pp.1016-1018

D. Wever, O. Derycke, L. Hendrix, A. De-meerleer, G. Godeau et al.,

, Soluble cadherins as cancer biomarkers, Clin. Exp. Metastasis, vol.24, pp.685-697

D. Wever, O. Van-bockstal, M. Mareel, M. Hendrix, A. Bracke et al., Carcinomaassociated fibroblasts provide operational flexibility in metastasis, Semin. Cancer Biol, vol.25, pp.33-46, 2014.

D. Rosario, M. Tsai, H. Dasanu, and C. A. , Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis, J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract, vol.24, pp.226-228, 2018.

G. T. Wolf, S. G. Fisher, W. K. Hong, R. Hillman, M. Spaulding et al.,

, N. Engl. J. Med, vol.324, pp.1685-1690

J. L. Depry, K. B. Reed, R. H. Cook-norris, and J. D. Brewer, Iatrogenic immunosuppression and cutaneous malignancy, Clin. Dermatol, vol.29, pp.602-613, 2011.

A. Desmoulière, M. Redard, I. Darby, and G. Gabbiani, , 1995.

N. Desprat, W. Supatto, P. Pouille, E. Beaurepaire, and E. Farge, , 2008.

L. A. Diaz, R. Williams, J. Wu, I. Kinde, J. R. Hecht et al., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, vol.486, pp.537-540, 2012.

M. T. Dimanche-boitrel, L. Vakaet, P. Pujuguet, B. Chauffert, M. S. Martin et al., In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts, Int. J. Cancer, vol.56, pp.512-521, 1994.

B. Dirat, L. Bochet, M. Dabek, D. Daviaud, S. Dauvillier et al., Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion, Cancer Res, vol.71, pp.2455-2465, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00819288

V. M. Dixit, S. Green, V. Sarma, L. B. Holzman, F. W. Wolf et al., , 1990.

, J. Biol. Chem, vol.265, pp.2973-2978

N. Do, S. Willenborg, B. Eckes, C. Jüngst, G. Sengle et al., , 2018.

, Myeloid Cell-Restricted STAT3 Signaling Controls a Cell-Autonomous Antifibrotic Repair Program

, J. Immunol. Baltim. Md, pp.663-674, 1950201.

B. Dong, G. Lv, Q. Wang, F. Wei, A. C. Bellail et al., Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells, Biochem. Biophys. Res. Commun, vol.418, pp.433-438, 2012.

H. Dong, G. Liu, Y. Hou, J. Wu, J. Lu et al., , 2007.

, Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro, J. Cancer Res. Clin. Oncol, vol.133, pp.83-92

J. M. Drake, N. A. Graham, T. Stoyanova, A. Sedghi, A. S. Goldstein et al., Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression, Proc. Natl. Acad. Sci. U. S. A, vol.109, pp.1643-1648, 2012.

G. D'souza, A. R. Kreimer, R. Viscidi, M. Pawlita, C. Fakhry et al., Case-control study of human papillomavirus and oropharyngeal cancer, 2007.

, J. Med, vol.356, pp.1944-1956

P. D. Dunne, D. G. Mcart, J. K. Blayney, M. Kalimutho, S. Greer et al., , 2014.

, J. Am. Assoc. Cancer Res, vol.20, pp.164-175

S. Dupont, L. Morsut, M. Aragona, E. Enzo, S. Giulitti et al., Role of YAP/TAZ in mechanotransduction, Nature, vol.474, pp.179-183, 2011.

M. Düwel, V. Welteke, A. Oeckinghaus, M. Baens, B. Kloo et al., A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains, J. Immunol. Baltim. Md, vol.182, pp.7718-7728, 1950.

H. F. Dvorak, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, N. Engl. J. Med, vol.315, pp.1650-1659, 1986.

B. Eckes, D. Kessler, M. Aumailley, and T. Krieg, Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis, Springer Semin. Immunopathol, vol.21, pp.415-429, 1999.

M. Egeblad, E. S. Nakasone, and Z. Werb, Tumors as organs: complex tissues that interface with the entire organism, Dev. Cell, vol.18, pp.884-901, 2010.

A. J. Ekstrand, N. Sugawa, C. D. James, and V. P. Collins, N-and/or C-terminal tails, Proc. Natl. Acad. Sci. U. S. A, vol.89, pp.4309-4313, 1992.

O. Elaskalani, N. B. Razak, M. Falasca, and P. Metharom, , 2017.

B. Elenbaas and R. A. Weinberg, Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation, Exp. Cell Res, vol.264, pp.169-184, 2001.

K. Elenius, C. J. Choi, S. Paul, E. Santiestevan, E. Nishi et al., Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase, Oncogene, vol.18, pp.2607-2615, 1999.

M. Elkabets, E. Pazarentzos, D. Juric, Q. Sheng, R. A. Pelossof et al., AXL mediates resistance to, 2015.

C. Frantz, K. M. Stewart, and V. M. Weaver, The extracellular matrix at a glance, J. Cell Sci, vol.123, pp.4195-4200, 2010.

Y. W. Fridell, Y. Jin, L. A. Quilliam, A. Burchert, P. Mccloskey et al., Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase, Mol. Cell. Biol, vol.16, pp.135-145, 1996.

J. C. Friedl, M. H. Lee, and D. Boettiger, Mechanically Activated Integrin Switch Controls a5b1 Function

S. L. Friedman, Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications, Nat. Clin. Pract. Gastroenterol. Hepatol, vol.1, pp.98-105, 2004.

S. M. Frisch, K. Vuori, E. Ruoslahti, C. , and P. Y. , Control of adhesion-dependent cell survival by focal adhesion kinase, J. Cell Biol, vol.134, pp.793-799, 1996.

A. Fritsch, S. Loeckermann, J. S. Kern, A. Braun, M. R. Bösl et al., A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy, J. Clin. Invest, vol.118, pp.1669-1679, 2008.

K. K. Fu, T. L. Phillips, I. J. Silverberg, C. Jacobs, D. R. Goffinet et al., Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial, J. Clin. Oncol, vol.5, pp.1410-1418, 1987.

K. K. Fu, J. S. Cooper, V. A. Marcial, G. E. Laramore, T. F. Pajak et al., Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer, Int. J. Radiat. Oncol. Biol. Phys, vol.35, pp.425-438, 1996.

D. Fukumura and R. K. Jain, Tumor microvasculature and microenvironment: Targets for antiangiogenesis and normalization, Microvasc. Res, vol.74, pp.72-84, 2007.

A. Fullár, J. Dudás, L. Oláh, P. Hollósi, Z. Papp et al., Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression, BMC Cancer, vol.15, p.256, 2015.

A. Furlan, V. Stagni, A. Hussain, S. Richelme, F. Conti et al., Abl interconnects oncogenic Met and p53 core pathways in cancer cells, Cell Death Differ, vol.18, pp.1608-1616, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00628278

M. A. Futterman, A. J. García, and E. A. Zamir, Evidence for partial epithelial-to-mesenchymal transition (pEMT) and recruitment of motile blastoderm edge cells during avian epiboly, Dev. Dyn. Off. Publ. Am. Assoc. Anat, vol.240, pp.1502-1511, 2011.

G. Gabbiani, G. I. Kaye, R. Lattes, and G. Majno, Synovial sarcoma Electron microscopic study of a typical case, Cancer, vol.28, pp.1031-1039, 1971.

C. Gaggioli, S. Hooper, C. Hidalgo-carcedo, R. Grosse, J. F. Marshall et al.,

, Nat. Cell Biol, vol.9, pp.1392-1400

I. García-tuñón, M. Ricote, A. Ruiz, B. Fraile, R. Paniagua et al., OSM, LIF, Its Receptors, and Its Relationship with the Malignance in Human Breast Carcinoma, Situ and in Infiltrative), vol.26, pp.222-229, 2008.

R. Garg, L. G. Benedetti, M. B. Abera, H. Wang, M. Abba et al., Protein kinase C and cancer: what we know and what we do not, Oncogene, vol.33, pp.5225-5237, 2014.

P. C. Georges, J. Hui, Z. Gombos, M. E. Mccormick, A. Y. Wang et al., Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis, Am. J. Physiol. Gastrointest. Liver Physiol, vol.293, pp.1147-1154, 2007.

L. E. Gerweck and K. Seetharaman, Cellular pH Gradient in Tumor versus Normal Tissue: Potential Exploitation for the Treatment of Cancer, Cancer Res, vol.56, pp.1194-1198, 1996.

E. Ghiso, C. Migliore, V. Ciciriello, E. Morando, A. Petrelli et al., YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC, vol.19, pp.1012-1021, 2017.

A. P. Gilmore, A. D. Metcalfe, L. H. Romer, and C. H. Streuli, Integrin-Mediated Survival Signals Regulate the Apoptotic Function of Bax through Its Conformation and Subcellular Localization, 2000.

, J. Cell Biol, vol.149, pp.431-446

R. Gioia, C. Trégoat, P. Dumas, V. Lagarde, V. Prouzet-mauléon et al., CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia, J. Pathol, vol.237, pp.14-24, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02400440

A. Givel, Y. Kieffer, A. Scholer-dahirel, P. Sirven, M. Cardon et al., miR200-regulated CXCL12? promotes fibroblast heterogeneity and immunosuppression in ovarian cancers, Nat. Commun, vol.9, p.1056, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02437797

C. Gjerdrum, C. Tiron, T. Høiby, I. Stefansson, H. Haugen et al., Axl is an essential epithelial-to-mesenchymal transitioninduced regulator of breast cancer metastasis and patient survival, Proc. Natl. Acad. Sci. U. S. A, vol.107, pp.1124-1129, 2010.

V. Gkretsi and T. Stylianopoulos, Cell Adhesion and Matrix Stiffness: Coordinating Cancer Cell Invasion and Metastasis, Front. Oncol, vol.8, 2018.

V. Gocheva, W. Zeng, D. Ke, D. Klimstra, T. Reinheckel et al.,

J. G. Goetz, S. Minguet, I. Navarro-lérida, J. J. Lazcano, R. Samaniego et al., Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis, Cell, vol.146, pp.148-163, 2011.

N. S. Goldstein, A. , and M. , Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system, Cancer, vol.92, pp.1331-1346, 2001.

N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.1, pp.1311-1318, 1995.

F. F. Gollin, J. , and R. O. , Pre-irradiation 5-fluorouracil infusion in advanced head and neck carcinomas, Cancer, vol.27, pp.768-770, 1971.

V. M. Golubovskaya and W. G. Cance, FAK and p53 Protein Interactions, Anticancer Agents Med. Chem, vol.11, pp.617-619, 2011.

Y. Gong, R. Somwar, K. Politi, M. Balak, J. Chmielecki et al., Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas, PLOS Med, vol.4, p.294, 2007.

J. Gore and M. Korc, Pancreatic cancer stroma: friend or foe?, Cancer Cell, vol.25, pp.711-712, 2014.

S. Goruppi, E. Ruaro, and C. Schneider, Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts, Oncogene, vol.12, pp.471-480, 1996.

S. Goruppi, E. Ruaro, B. Varnum, and C. Schneider, Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts, Mol. Cell. Biol, vol.17, pp.4442-4453, 1997.

M. Goyette, S. Duhamel, L. Aubert, A. Pelletier, P. Savage et al., The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression, Cell Rep, vol.23, pp.1476-1490, 2018.

M. M. Grabowska, B. Sandhu, and M. L. Day, EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells, Cell. Signal, vol.24, pp.532-538, 2012.

D. K. Graham, T. L. Dawson, D. L. Mullaney, H. R. Snodgrass, and H. S. Earp, Cloning and mRNA expression analysis of a novel human protooncogene, c-mer, Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res, vol.5, pp.647-657, 1994.

D. K. Graham, D. Deryckere, K. D. Davies, and H. S. Earp, The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer, Nat. Rev. Cancer, vol.14, pp.769-785, 2014.

J. R. Grandis and D. J. Tweardy, , 1993.

C. Grashoff, B. D. Hoffman, M. D. Brenner, R. Zhou, M. Parsons et al., Measuring mechanical tension across vinculin reveals regulation of focal adhesion dynamics, Nature, vol.466, pp.263-266, 2010.

E. M. Grasset, T. Bertero, A. Bozec, J. Friard, I. Bourget et al., Matrix Stiffening and EGFR Cooperate to Promote the Collective Invasion of Cancer Cells, Cancer Res, vol.78, pp.5229-5242, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02347409

E. K. Greuber, P. Smith-pearson, J. Wang, and A. M. Pendergast, Role of ABL Family Kinases in Cancer: from Leukemia to Solid Tumors, Nat. Rev. Cancer, vol.13, p.559, 2013.

C. Gridelli, S. Peters, A. Sgambato, F. Casaluce, A. A. Adjei et al., ALK inhibitors in the treatment of advanced NSCLC, Cancer Treat. Rev, vol.40, pp.300-306, 2014.

A. D. Grigore, M. K. Jolly, D. Jia, M. C. Farach-carson, and H. Levine, Tumor Budding: The Name is EMT, Partial EMT. J. Clin. Med, vol.5, 2016.

A. Grosse-wilde, A. Fouquier-d'hérouël, E. Mcintosh, G. Ertaylan, A. Skupin et al., Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival, PloS One, vol.10, p.126522, 2015.

A. Gschwind, S. Hart, O. M. Fischer, and A. Ullrich, TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells, EMBO J, vol.22, pp.2411-2421, 2003.

A. Gschwind, O. M. Fischer, and A. Ullrich, The discovery of receptor tyrosine kinases: targets for cancer therapy, Nat. Rev. Cancer, vol.4, pp.361-370, 2004.

L. Guerra, T. Odorisio, G. Zambruno, and D. Castiglia, Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development, Matrix Biol. J. Int. Soc. Matrix Biol, vol.63, pp.1-10, 2017.

P. W. Gunning, E. C. Hardeman, P. Lappalainen, and D. P. Mulvihill, Tropomyosin -master regulator of actin filament function in the cytoskeleton, J. Cell Sci, vol.128, pp.2965-2974, 2015.

S. Gusenbauer, P. Vlaicu, and A. Ullrich, HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors, Oncogene, vol.32, pp.3846-3856, 2013.

A. Gustafsson, D. Martuszewska, M. Johansson, C. Ekman, S. Hafizi et al., Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.15, pp.4742-4749, 2009.

R. I. Haddad, M. Posner, R. Hitt, E. E. Cohen, J. Schulten et al.,

, neck: role, controversy, and future directions, Ann. Oncol, vol.29, pp.1130-1140

S. Hafizi and B. Dahlbäck, Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily, FEBS J, vol.273, pp.5231-5244, 2006.

S. Hafizi, F. Alindri, R. Karlsson, and B. Dahlbäck, Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin, Biochem. Biophys. Res. Commun, vol.299, pp.793-800, 2002.

S. Hafizi, F. Ibraimi, and B. Dahlbäck, C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol, vol.19, pp.971-973, 2005.

G. Halder, J. , and R. L. , Hippo signaling: growth control and beyond, Dev. Camb. Engl, vol.138, pp.9-22, 2011.

T. Hama, Y. Yuza, Y. Saito, J. O-uchi, S. Kondo et al., Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma, The Oncologist, vol.14, pp.900-908, 2009.

K. Hamamura, G. Swarnkar, N. Tanjung, E. Cho, J. Li et al., RhoAmediated signaling in mechanotransduction of osteoblasts, Connect. Tissue Res, vol.53, pp.398-406, 2012.

H. Hamidi and J. Ivaska, Every step of the way: integrins in cancer progression and metastasis, 2018.

, Nat. Rev. Cancer, vol.18, p.533

J. Han, R. Tian, B. Yong, C. Luo, P. Tan et al., Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients, Biochem. Biophys. Res. Commun, vol.435, pp.493-500, 2013.

D. Hanahan and L. M. Coussens, Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment, Cancer Cell, vol.21, pp.309-322, 2012.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

D. Harari, E. Tzahar, J. Romano, M. Shelly, J. H. Pierce et al., , 1999.

, Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase, Oncogene, vol.18, pp.2681-2689

D. S. Harburger and D. A. Calderwood, Integrin signalling at a glance, J. Cell Sci, vol.122, pp.159-163, 2009.

L. Harrison and K. Blackwell, Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy?, The Oncologist, vol.9, pp.31-40, 2004.

I. Hasanbasic, J. Cuerquis, B. Varnum, and M. D. Blostein, Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells, Am. J. Physiol. Heart Circ. Physiol, vol.287, pp.1207-1213, 2004.

S. Hattori, E. Kikuchi, T. Kosaka, Y. Miyazaki, N. Tanaka et al.,

, Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma, Ann. Surg. Oncol, vol.23, pp.663-670

E. D. Hay, An overview of epithelio-mesenchymal transformation, Acta Anat. (Basel), vol.154, pp.8-20, 1995.

M. Hayashi, Y. Yamamoto, M. Ibusuki, S. Fujiwara, S. Yamamoto et al., , 2012.

, Ann. Surg. Oncol, vol.19, pp.3042-3049

R. B. Hazan, N. , and L. , The Epidermal Growth Factor Receptor Modulates the Interaction of E-cadherin with the Actin Cytoskeleton, J. Biol. Chem, vol.273, pp.9078-9084, 1998.

A. Hector, E. A. Montgomery, C. Karikari, M. Canto, K. B. Dunbar et al., The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma, Cancer Biol. Ther, vol.10, pp.1009-1018, 2010.

M. L. Hinni, A. Ferlito, M. S. Brandwein-gensler, R. P. Takes, C. E. Silver et al., Surgical margins in head and neck cancer: a contemporary review, Head Neck, vol.35, pp.1362-1370, 2013.

B. Hinz, Formation and Function of the Myofibroblast during Tissue Repair, J. Invest. Dermatol, vol.127, pp.526-537, 2007.

B. Hinz, G. Celetta, J. J. Tomasek, G. Gabbiani, and C. Chaponnier, Alpha-Smooth Muscle Actin Expression Upregulates Fibroblast Contractile Activity, Mol. Biol. Cell, vol.12, pp.2730-2741, 2001.

B. Hinz, G. Gabbiani, and C. Chaponnier, The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo, J. Cell Biol, vol.157, pp.657-663, 2002.

E. Hirata, M. R. Girotti, A. Viros, S. Hooper, B. Spencer-dene et al., Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin ?1/FAK signaling, Cancer Cell, vol.27, pp.574-588, 2015.

A. B. Hjelmeland, Q. Wu, S. Wickman, C. Eyler, J. Heddleston et al., Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth, PLOS Biol, vol.8, p.1000319, 2010.

R. Hofheinz, S. Batran, F. Hartmann, G. Hartung, D. Jäger et al., Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer, Onkologie, vol.26, pp.44-48, 2003.

L. E. Hokin, Effects of calcium omission on acetylcholine-stimulated amylase secretion and phospholipid synthesis in pigeon pancreas slices, Biochim. Biophys. Acta, vol.115, pp.219-221, 1966.

S. J. Holland, A. Pan, C. Franci, Y. Hu, B. Chang et al., R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer, Cancer Res, vol.70, pp.1544-1554, 2010.

J. J. Homer, Surgery in head and neck cancer: United Kingdom National Multidisciplinary Guidelines, J. Laryngol. Otol, vol.130, pp.68-70, 2016.

W. Hong and K. Guan, The YAP and TAZ transcription coactivators: key downstream effectors of the mammalian Hippo pathway, Semin. Cell Dev. Biol, vol.23, pp.785-793, 2012.

C. Hong, J. Lay, J. Huang, A. Cheng, J. Tang et al., , 2008.

J. Hong, D. Peng, Z. Chen, V. Sehdev, and A. Belkhiri, ABL regulation by AXL promotes cisplatin resistance in esophageal cancer, Cancer Res, vol.73, pp.331-340, 2013.

T. Hong, K. Watanabe, C. H. Ta, A. Villarreal-ponce, Q. Nie et al., An Ovol2-Zeb1, 2015.

, Mutual Inhibitory Circuit Governs Bidirectional and Multi-step Transition between Epithelial and Mesenchymal States, PLoS Comput. Biol, vol.11, p.1004569

S. Hopps, P. Medina, S. Pant, R. Webb, M. Moorman et al., Cetuximab hypersensitivity infusion reactions: Incidence and risk factors, J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract, vol.19, pp.222-227, 2013.

E. R. Horton, A. Byron, J. A. Askari, D. H. Ng, A. Millon-frémillon et al., Definition of a consensus integrin adhesome and its dynamics during adhesion complex assembly and disassembly, Nat. Cell Biol, vol.17, pp.1577-1587, 2015.

E. R. Horton, J. D. Humphries, J. James, M. C. Jones, J. A. Askari et al., The integrin adhesome network at a glance, J. Cell Sci, vol.129, pp.4159-4163, 2016.

K. Hotta, S. Ranganathan, R. Liu, F. Wu, H. Machiyama et al., Biophysical Properties of Intrinsically Disordered p130Cas Substrate Domain -Implication in Mechanosensing, PLOS Comput. Biol, vol.10, p.1003532, 2014.

M. Hsieh, P. Yang, L. Wong, and J. Lee, , 2016.

H. Huang, H. Seo, T. Zhang, Y. Wang, B. Jiang et al., , 2017.

P. H. Huang, A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer et al., Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma, Proc. Natl. Acad. Sci. U. S. A, vol.104, pp.12867-12872, 2007.

M. A. Huber, N. Azoitei, B. Baumann, S. Grünert, A. Sommer et al., NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression, J. Clin. Invest, vol.114, pp.569-581, 2004.

J. D. Humphries, A. Byron, and M. J. Humphries, Integrin ligands at a glance, J. Cell Sci, vol.119, pp.3901-3903, 2006.

H. Hurwitz and F. Kabbinavar, Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer, Oncology, vol.69, pp.17-24, 2005.

H. I. Hurwitz, N. Uppal, S. A. Wagner, J. C. Bendell, J. T. Beck et al., Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed, J. Clin. Oncol, vol.33, pp.4039-4047, 2015.

S. P. Hussain and C. C. Harris, p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis, J. Nippon Med. Sch. Nippon Ika Daigaku Zasshi, vol.73, pp.54-64, 2006.

M. Hutterer, P. Knyazev, A. Abate, M. Reschke, H. Maier et al., , 2008.

, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.14, pp.130-138

J. E. Hutti, B. E. Turk, J. M. Asara, A. Ma, L. C. Cantley et al., IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway, Mol. Cell. Biol, vol.27, pp.7451-7461, 2007.

J. Huynh, N. Etemadi, F. Hollande, M. Ernst, and M. Buchert, The JAK/STAT3 axis: A comprehensive drug target for solid malignancies, Semin. Cancer Biol, vol.45, pp.13-22, 2017.

R. O. Hynes, Integrins: bidirectional, allosteric signaling machines, Cell, vol.110, pp.673-687, 2002.

R. A. Ignotz and J. Massagué, Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix, J. Biol. Chem, vol.261, pp.4337-4345, 1986.

L. J. Inge, S. P. Barwe, J. D'ambrosio, J. Gopal, K. Lu et al., Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor, Exp. Cell Res, vol.317, pp.838-848, 2011.

L. R. Intong and D. F. Murrell, Inherited epidermolysis bullosa: new diagnostic criteria and classification, Clin. Dermatol, vol.30, pp.70-77, 2012.

M. Inukai, S. Toyooka, S. Ito, H. Asano, S. Ichihara et al., , 2006.

R. V. Iozzo, Matrix proteoglycans: from molecular design to cellular function, Annu. Rev. Biochem, vol.67, pp.609-652, 1998.

J. Ishitoya, M. Toriyama, N. Oguchi, K. Kitamura, M. Ohshima et al.,

, Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck, Br. J. Cancer, vol.59, pp.559-562

D. E. Jaalouk and J. Lammerding, Mechanotransduction gone awry, Nat. Rev. Mol. Cell Biol, vol.10, pp.63-73, 2009.

D. Jackman, W. Pao, G. J. Riely, J. A. Engelman, M. G. Kris et al., Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer, J. Clin. Oncol, vol.28, pp.357-360, 2010.

P. A. Janmey, R. G. Wells, R. K. Assoian, and C. A. Mcculloch, From tissue mechanics to transcription factors, Differ. Res. Biol. Divers, vol.86, pp.112-120, 2013.

M. Janning, I. Ben-batalla, and S. Loges, Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?, Expert Rev. Hematol, vol.8, pp.135-138, 2015.

R. Jano?tiak, A. C. Pataki, J. Brábek, and D. Rösel, Mechanosensors in integrin signaling: The emerging role of p130Cas, Eur. J. Cell Biol, vol.93, pp.445-454, 2014.

S. Jean and A. A. Kiger, Classes of phosphoinositide 3-kinases at a glance, J. Cell Sci, vol.127, pp.923-928, 2014.

F. Jerhammar, A. Johansson, R. Ceder, J. Welander, A. Jansson et al., , 2014.

T. Jiang, G. Liu, L. Wang, and H. Liu, Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma, PloS One, vol.10, 2015.

R. Jinka, R. Kapoor, P. G. Sistla, T. A. Raj, and G. Pande, Alterations in Cell-Extracellular Matrix Interactions during Progression of Cancers, 2012.

A. Johansson, A. Ansell, F. Jerhammar, M. B. Lindh, R. Grénman et al., Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells, Mol. Cancer Res. MCR, vol.10, pp.1158-1168, 2012.

M. John, Understanding Radiotherapy for Head and Neck Cancer: A Guide for Adults and Their Caregivers, Eisenberg Center for Clinical Decisions and CommunicationsScience, p.p, 2005.

J. T. Johnson, R. L. Wagner, and E. N. Myers, , 1996.

L. A. Johnson, E. S. Rodansky, K. L. Sauder, J. C. Horowitz, J. D. Mih et al., Matrix Stiffness Corresponding to Strictured Bowel Induces a Fibrogenic Response in Human Colonic Fibroblasts, Inflamm. Bowel Dis, vol.19, pp.891-903, 2013.

M. K. Jolly, M. Boareto, B. Huang, D. Jia, M. Lu et al.,

N. V. Jordan, G. L. Johnson, and A. N. Abell, Tracking the intermediate stages of epithelialmesenchymal transition in epithelial stem cells and cancer, Cell Cycle Georget. Tex, vol.10, pp.2865-2873, 2011.

J. A. Joyce, Therapeutic targeting of the tumor microenvironment, Cancer Cell, vol.7, pp.513-520, 2005.

M. H. Joyce, C. Lu, E. R. James, R. Hegab, S. C. Allen et al., , 2015.

, High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa, Mol. Ther. J. Am. Soc. Gene Ther, vol.23, pp.1368-1379

D. I. Kutler, A. D. Auerbach, J. Satagopan, P. F. Giampietro, S. D. Batish et al., High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia, Arch. Otolaryngol. Head Neck Surg, vol.129, pp.106-112, 2003.

V. Küttner, C. Mack, C. Gretzmeier, L. Bruckner-tuderman, and J. Dengjel, Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity, J. Invest. Dermatol, vol.134, pp.2381-2389, 2014.

S. Kuzet and C. Gaggioli, Fibroblast activation in cancer: when seed fertilizes soil, Cell Tissue Res, vol.365, pp.607-619, 2016.

S. Kuzet and C. Gaggioli, Fibroblast activation in cancer: when seed fertilizes soil, Cell Tissue Res, vol.365, pp.607-619, 2016.

J. Kwong, K. Lo, K. To, P. M. Teo, P. J. Johnson et al., , 2002.

A. Labernadie, T. Kato, A. Brugués, X. Serra-picamal, S. Derzsi et al., A mechanically active heterotypic Ecadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion, Nat. Cell Biol, vol.19, pp.224-237, 2017.

C. Lai, M. Gore, and G. Lemke, Structure, expression, and activity of Tyro 3, a neural adhesionrelated receptor tyrosine kinase, Oncogene, vol.9, pp.2567-2578, 1994.

C. J. Langer, J. W. Lee, U. A. Patel, D. M. Shin, A. E. Argiris et al., Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), J. Clin. Oncol, vol.26, pp.6006-6006, 2008.

A. O. Langlands, Radiation therapy in the treatment of cancer: the past, the present, and the future, Aust. N. Z. J. Surg, vol.52, pp.331-335, 1982.

G. E. Laramore, C. B. Scott, M. Sarraf, R. E. Haselow, T. J. Ervin et al., Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034, Int. J. Radiat. Oncol. Biol. Phys, vol.23, pp.705-713, 1992.

P. Laurent-puig, A. Cayre, G. Manceau, E. Buc, J. Bachet et al., Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.5924-5930, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00618089

A. Lavaf, E. M. Genden, J. A. Cesaretti, S. Packer, and J. Kao, , 2008.

J. Lay, C. Hong, J. Huang, Y. Yang, C. Pao et al., Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL, Cancer Res, vol.67, pp.3878-3887, 2007.

W. Leconet, C. Larbouret, T. Chardès, G. Thomas, M. Neiveyans et al., Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy, Oncogene, vol.33, pp.5405-5414, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-00916587

W. Lederle, B. Hartenstein, A. Meides, H. Kunzelmann, Z. Werb et al.,

J. W. Lee, J. , and R. , Mitogenic signal transduction by integrin-and growth factor receptormediated pathways, Mol. Cells, vol.17, pp.188-202, 2004.

C. Lee, C. Yen, S. Liu, C. Chen, C. Chiang et al., , 2012.

E. G. Lee, D. L. Boone, S. Chai, S. L. Libby, M. Chien et al., Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice, Science, vol.289, pp.2350-2354, 2000.

H. Lee, A. Herrmann, J. Deng, M. Kujawski, G. Niu et al., Persistently Activated Stat3 Maintains Constitutive NF-?B Activity in Tumors, vol.15, pp.283-293, 2009.

J. E. Lee, H. S. Park, D. Lee, G. Yoo, T. Kim et al., Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance, Biochem. Biophys. Res. Commun, vol.474, pp.154-160, 2016.

J. Lee, S. M. Jung, K. Yang, E. Bae, S. G. Ahn et al., A20 promotes metastasis of aggressive basal-like breast cancers through multimonoubiquitylation of Snail1, Nat. Cell Biol, vol.19, pp.1260-1273, 2017.

J. J. Lee, R. M. Perera, H. Wang, D. Wu, X. S. Liu et al., Stromal response to Hedgehog signaling restrains pancreatic cancer progression, Proc. Natl. Acad. Sci. U. S. A, vol.111, pp.3091-3100, 2014.

K. Lee, S. S. Lee, S. Kim, B. H. Sohn, H. Lee et al., Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.21, pp.357-364, 2015.

C. R. Leemans, B. J. Braakhuis, and R. H. Brakenhoff, The molecular biology of head and neck cancer, Nat. Rev. Cancer, vol.11, pp.9-22, 2011.

J. L. Lefebvre, D. Chevalier, B. Luboinski, A. Kirkpatrick, L. Collette et al., Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial, 1996.

, J. Natl. Cancer Inst, vol.88, pp.890-899

J. L. Leight, M. A. Wozniak, S. Chen, M. L. Lynch, C. et al., Matrix rigidity regulates a switch between TGF-?1-induced apoptosis and epithelial-mesenchymal transition, Mol. Biol. Cell, vol.23, pp.781-791, 2012.

B. Leitinger and E. Hohenester, Mammalian collagen receptors, Matrix Biol. J. Int. Soc. Matrix Biol, vol.26, pp.146-155, 2007.

G. Lemke, Biology of the TAM receptors, Cold Spring Harb. Perspect. Biol, vol.5, p.9076, 2013.

G. Lemke and C. V. Rothlin, Immunobiology of the TAM receptors, Nat. Rev. Immunol, vol.8, pp.327-336, 2008.

I. Lerner, E. Hermano, E. Zcharia, D. Rodkin, R. Bulvik et al., Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice, J. Clin. Invest, vol.121, pp.1709-1721, 2011.

K. R. Levental, H. Yu, L. Kass, J. N. Lakins, M. Egeblad et al., , 2009.

G. Levkowitz, H. Waterman, S. A. Ettenberg, M. Katz, A. Y. Tsygankov et al., Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1, Mol. Cell, vol.4, pp.1029-1040, 1999.

L. J. Lewis-tuffin, F. Rodriguez, C. Giannini, B. Scheithauer, B. M. Necela et al., Misregulated E-Cadherin Expression Associated with an Aggressive Brain Tumor Phenotype, PLOS ONE, vol.5, 2010.

J. Ley, P. Mehan, T. M. Wildes, W. Thorstad, H. A. Gay et al., Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma, Oncology, vol.85, pp.290-296, 2013.

L. Li, J. Li, and J. Gao, Functions of galectin-3 and its role in fibrotic diseases, J. Pharmacol. Exp. Ther, vol.351, pp.336-343, 2014.

Q. Li, A. Hata, C. Kosugi, N. Kataoka, and M. Funaki, The density of extracellular matrix proteins regulates inflammation and insulin signaling in adipocytes, FEBS Lett, vol.584, pp.4145-4150, 2010.

R. Li, W. Zhao, F. Fang, C. Zhuang, X. Zhang et al., Lysyl oxidase-like 4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src pathway, J. Cancer Res. Clin. Oncol, vol.141, pp.269-281, 2015.

Y. Li, X. Ye, C. Tan, J. Hongo, J. Zha et al., , 2009.

, Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis, Oncogene, vol.28, pp.3442-3455

K. Liang, K. K. Ang, L. Milas, N. Hunter, F. et al., The epidermal growth factor receptor mediates radioresistance, Int. J. Radiat. Oncol, vol.57, pp.246-254, 2003.

A. Lièvre, J. Bachet, D. Le-corre, V. Boige, B. Landi et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.66, pp.3992-3995, 2006.

C. P. Lim, T. Phan, I. J. Lim, and X. Cao, Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration, Oncogene, vol.25, pp.5416-5425, 2006.

S. Lim, X. L. Chen, Y. Lim, D. A. Hanson, T. Vo et al., Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation, Mol. Cell, vol.29, pp.9-22, 2008.

S. Lin and L. Gu, Influence of Crosslink Density and Stiffness on Mechanical Properties of Type I Collagen Gel, Materials, vol.8, pp.551-560, 2015.

R. Lin, L. Yang, P. Nakhaei, Q. Sun, E. Sharif-askari et al., Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20, J. Biol. Chem, vol.281, pp.2095-2103, 2006.

R. M. Linger, A. K. Keating, H. S. Earp, and D. K. Graham, TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer, Adv. Cancer Res, vol.100, pp.35-83, 2008.

S. M. Lippman, S. E. Benner, and W. K. Hong, Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis, Cancer Res, vol.54, pp.2025-2028, 1994.

R. I. Litvinov, V. Barsegov, A. J. Schissler, A. R. Fisher, J. S. Bennett et al.,

H. Liu, Y. Wu, T. Lv, Y. Yao, Y. Xiao et al., Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, PLoS ONE, vol.8, 2013.

J. Liu, K. Wang, Z. Yan, Y. Xia, J. Li et al., , 2016.

, Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma, PloS One, vol.11, 154767.

K. Liu, H. Yao, Y. Wen, H. Zhao, N. Zhou et al., Functional role of a long non-coding RNA LIFR-AS1/miR-29a/TNFAIP3 axis in colorectal cancer resistance to pohotodynamic therapy, Biochim. Biophys. Acta Mol. Basis Dis, vol.1864, pp.2871-2880, 2018.

Z. Liu, Y. E. Hartman, J. M. Warram, J. A. Knowles, L. Sweeny et al., , 2011.

, Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells, Mol. Cancer Res. MCR, vol.9, pp.1008-1017

C. M. Lo, H. B. Wang, M. Dembo, and Y. L. Wang, , 2000.

S. López-verdín, J. Lavalle-carrasco, R. G. Carreón-burciaga, N. Serafín-higuera, N. Molina-frechero et al., Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review, Cancers, vol.10, 2018.

P. Lu, V. M. Weaver, and Z. Werb, The extracellular matrix: A dynamic niche in cancer progression, J Cell Biol, vol.196, pp.395-406, 2012.

Q. Lu, M. Gore, Q. Zhang, T. Camenisch, S. Boast et al., , 1999.

V. W. Lui, M. L. Hedberg, H. Li, B. S. Vangara, K. Pendleton et al., Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers, Cancer Discov, vol.3, pp.761-769, 2013.

W. S. Maccomb and G. H. Fletcher, Planned combination of surgery and radiation in treatment of advanced primary head and neck cancers, Am. J. Roentgenol. Radium Ther. Nucl. Med, vol.77, pp.397-414, 1957.

E. Macias, D. Rao, and J. Digiovanni, Role of stat3 in skin carcinogenesis: insights gained from relevant mouse models, J. Skin Cancer, p.684050, 2013.

S. M. Magrini, M. Buglione, R. Corvò, L. Pirtoli, F. Paiar et al., Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial, J. Clin. Oncol, vol.34, pp.427-435, 2015.

I. Malanchi, A. Santamaria-martínez, E. Susanto, H. Peng, H. Lehr et al., Interactions between cancer stem cells and their niche govern metastatic colonization, Nature, vol.481, pp.85-89, 2011.

E. Malone and L. L. Siu, Precision Medicine in Head and Neck Cancer: Myth or Reality? Clin, 2018.

, Med. Insights Oncol, vol.12

A. Mammoto, K. M. Connor, T. Mammoto, C. W. Yung, D. Huh et al., A mechanosensitive transcriptional mechanism that controls angiogenesis, Nature, vol.457, pp.1103-1108, 2009.

S. A. Mani, W. Guo, M. Liao, E. N. Eaton, A. Ayyanan et al., The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells, Cell, vol.133, pp.704-715, 2008.

H. Martin, B. Del-valle, H. Ehrlich, and W. G. Cahan, Neck dissection, Cancer, vol.4, pp.441-499, 1951.

L. Marzi, E. Combes, N. Vié, A. Ayrolles-torro, D. Tosi et al., , 2016.

, Br. J. Cancer, vol.115, pp.1223-1233

C. Mas-moruno, F. Rechenmacher, and H. Kessler, Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation, Anticancer Agents Med. Chem, vol.10, pp.753-768, 2010.

Y. Matsuo, N. Ochi, H. Sawai, A. Yasuda, H. Takahashi et al., CXCL8/IL-8 and CXCL12/SDF-1? Co-operatively Promote Invasiveness and Angiogenesis in Pancreatic Cancer, Int. J. Cancer J. Int. Cancer, vol.124, pp.853-861, 2009.

S. Matsuzaki, C. Darcha, J. Pouly, and M. Canis, Effects of matrix stiffness on epithelial to mesenchymal transition-like processes of endometrial epithelial cells: Implications for the pathogenesis of endometriosis, Sci. Rep, vol.7, p.44616, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01655210

B. F. Matte, A. Kumar, J. K. Placone, V. G. Zanella, M. D. Martins et al.,

M. Maurizi, G. Almadori, G. Ferrandina, M. Distefano, M. E. Romanini et al., Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma, Br. J. Cancer, vol.74, pp.1253-1257, 1996.

P. H. Mead, Surgery or radiotherapy for tonsil cancer?, Cancer, vol.16, pp.195-198, 1963.

M. B. Meads, R. A. Gatenby, and W. S. Dalton, Environment-mediated drug resistance: a major contributor to minimal residual disease, Nat. Rev. Cancer, vol.9, pp.665-674, 2009.

L. M. Meenderink, L. M. Ryzhova, D. M. Donato, D. F. Gochberg, I. Kaverina et al.,

, P130Cas Src-Binding and Substrate Domains Have Distinct Roles in Sustaining Focal Adhesion Disassembly and Promoting Cell Migration, PLoS ONE, vol.5

J. Mendelsohn and J. Baselga, The EGF receptor family as targets for cancer therapy, Oncogene, vol.19, pp.6550-6565, 2000.

W. M. Mendenhall, C. G. Morris, R. J. Amdur, R. W. Hinerman, R. S. Malyapa et al., Definitive radiotherapy for tonsillar squamous cell carcinoma, Am. J. Clin. Oncol, vol.29, pp.290-297, 2006.

S. Menon and K. A. Beningo, Cancer Cell Invasion Is Enhanced by Applied Mechanical Stimulation, PLOS ONE, vol.6, 2011.

L. M. Merlo, J. W. Pepper, B. J. Reid, and C. C. Maley, Cancer as an evolutionary and ecological process, Nat. Rev. Cancer, vol.6, pp.924-935, 2006.

A. S. Meyer, M. A. Miller, F. B. Gertler, and D. A. Lauffenburger, , 2013.

B. W. Miller, J. P. Morton, M. Pinese, G. Saturno, N. B. Jamieson et al., Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy, EMBO Mol. Med, vol.7, pp.1063-1076, 2015.

R. R. Million, J. T. Parsons, and N. J. Cassisi, Twice-a-day irradiation technique for squamous cell carcinomas of the head and neck, Cancer, vol.55, pp.2096-2099, 1985.

T. Minami, K. Kuwahara, Y. Nakagawa, M. Takaoka, H. Kinoshita et al., Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice, EMBO J, vol.31, pp.4428-4440, 2012.

F. Miralles, G. Posern, A. Zaromytidou, and R. Treisman, Actin Dynamics Control SRF Activity by Regulation of Its Coactivator MAL. Cell, vol.113, pp.329-342, 2003.

S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.486, pp.532-536, 2012.

P. Mishra, D. Banerjee, and A. Ben-baruch, Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy, J. Leukoc. Biol, vol.89, pp.31-39, 2011.

V. R. Mittapalli, J. Madl, S. Löffek, D. Kiritsi, J. S. Kern et al., Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression, Cancer Res, vol.76, pp.940-951, 2016.

H. Mohammadi and E. Sahai, Mechanisms and impact of altered tumour mechanics, Nat. Cell Biol, vol.20, p.766, 2018.

P. S. Mongroo and A. K. Rustgi, The role of the miR-200 family in epithelial-mesenchymal transition, Cancer Biol. Ther, vol.10, pp.219-222, 2010.

C. Montagut, A. Dalmases, B. Bellosillo, M. Crespo, S. Pairet et al., , 2012.

G. S. Montana, S. Hellman, C. F. Von-essen, and M. M. Kligerman, Carcinoma of the tongue and floor of the mouth. Results of radical radiotherapy, Cancer, vol.23, pp.1284-1289, 1969.

G. Moody, B. Belmontes, S. Masterman, W. Wang, C. King et al., Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo, Int. J. Cancer, vol.139, pp.1340-1349, 2016.

S. W. Moore and M. P. Sheetz, Biophysics of substrate interaction: influence on neural motility, differentiation and repair, Dev. Neurobiol, vol.71, pp.1090-1101, 2011.

S. Morandell, T. Stasyk, K. Grosstessner-hain, E. Roitinger, K. Mechtler et al., Phosphoproteomics strategies for the functional analysis of signal transduction, Proteomics, vol.6, pp.4047-4056, 2006.

J. K. Mouw, Y. Yui, L. Damiano, R. O. Bainer, J. N. Lakins et al., Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression, Nat. Med, vol.20, pp.360-367, 2014.

M. M. Mueller and N. E. Fusenig, , 2004.

S. Mukherjee, The emperor of all maladies: a biography of cancer, 2010.

K. Münger and P. M. Howley, Human papillomavirus immortalization and transformation functions, Virus Res, vol.89, pp.213-228, 2002.

C. Murdoch, M. Muthana, S. B. Coffelt, and C. E. Lewis, The role of myeloid cells in the promotion of tumour angiogenesis, Nat. Rev. Cancer, vol.8, pp.618-631, 2008.

A. K. Murugan, N. T. Hong, Y. Fukui, A. K. Munirajan, and N. Tsuchida, Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas, Int. J. Oncol, vol.32, pp.101-111, 2008.

J. Myllyharju and K. I. Kivirikko, Collagens, modifying enzymes and their mutations in humans, flies and worms, Trends Genet. TIG, vol.20, pp.33-43, 2004.

K. Nagata, K. Ohashi, T. Nakano, H. Arita, C. Zong et al., for Axl, Sky, and Mer receptor tyrosine kinases, J. Biol. Chem, vol.271, pp.30022-30027, 1996.

A. J. Najy, K. C. Day, and M. L. Day, The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation, J. Biol. Chem, vol.283, pp.18393-18401, 2008.

K. Nakamura, Y. Shioyama, M. Kawashima, Y. Saito, N. Nakamura et al., Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy, Int. J. Radiat. Oncol. Biol. Phys, vol.65, pp.1045-1050, 2006.

S. S. Napier and P. M. Speight, Natural history of potentially malignant oral lesions and conditions: an overview of the literature, J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am, 2008.

. Acad, Oral Pathol, vol.37, pp.1-10

P. A. Netti, D. A. Berk, M. A. Swartz, A. J. Grodzinsky, and R. K. Jain, Role of extracellular matrix assembly in interstitial transport in solid tumors, Cancer Res, vol.60, pp.2497-2503, 2000.

J. M. Ng and T. Curran, The Hedgehog's tale: developing strategies for targeting cancer, Nat. Rev. Cancer, vol.11, pp.493-501, 2011.

K. P. Ng, A. M. Hillmer, C. T. Chuah, W. C. Juan, T. K. Ko et al., A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer, Nat. Med, vol.18, pp.521-528, 2012.

Y. Ng, C. Pourreyron, J. C. Salas-alanis, J. H. Dayal, R. Cepeda-valdes et al., , 2012.

S. M. Nielsen-preiss, M. P. Allen, M. Xu, D. A. Linseman, J. E. Pawlowski et al., Adhesion-related kinase induction of migration requires phosphatidylinositol-3-kinase and ras stimulation of rac activity in immortalized gonadotropinreleasing hormone neuronal cells, Endocrinology, vol.148, pp.2806-2814, 2007.

M. T. Nieman, R. S. Prudoff, K. R. Johnson, and M. J. Wheelock, , 1999.

L. J. Nissen, R. Cao, E. Hedlund, Z. Wang, X. Zhao et al., Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis, J. Clin. Invest, vol.117, pp.2766-2777, 2007.

S. Noguchi, A. Saito, Y. Mikami, H. Urushiyama, M. Horie et al., , 2017.

Y. Nong, D. Wu, Y. Lin, Y. Zhang, L. Bai et al., Tenascin-C expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients and the inflammatory cytokine TNF?-induced TNC expression promotes migration in HCC cells, Am. J. Cancer Res, vol.5, pp.782-791, 2015.

N. Normanno, C. Bianco, A. De-luca, M. R. Maiello, and D. S. Salomon, Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment, Endocr. Relat. Cancer, vol.10, pp.1-21, 2003.

U. Novak, A. Rinaldi, I. Kwee, S. V. Nandula, P. M. Rancoita et al., The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas, Blood, vol.113, pp.4918-4921, 2009.

A. Nukuda, C. Sasaki, S. Ishihara, T. Mizutani, K. Nakamura et al., Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression, vol.4, p.165, 2015.

G. Numico, P. Franco, A. Cristofano, F. Migliaccio, S. Spinazzé et al., Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence, Crit. Rev. Oncol. Hematol, vol.85, pp.112-120, 2013.

A. Nyström and L. Bruckner-tuderman, Injury-and inflammation-driven skin fibrosis: The paradigm of epidermolysis bullosa, Matrix Biol. J. Int. Soc. Matrix Biol, pp.547-560, 2018.

A. Nyström, D. Velati, V. R. Mittapalli, A. Fritsch, J. S. Kern et al., , 2013.

, Collagen VII plays a dual role in wound healing, J. Clin. Invest, vol.123, pp.3498-3509

A. Nyström, K. Thriene, V. Mittapalli, J. S. Kern, D. Kiritsi et al.,

, Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms, EMBO Mol. Med, vol.7, pp.1211-1228

A. Nyström, O. Bornert, T. Kühl, C. Gretzmeier, K. Thriene et al., Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa, Proc. Natl. Acad. Sci. U. S. A, vol.115, pp.705-714, 2018.

J. P. O'bryan, R. A. Frye, P. C. Cogswell, A. Neubauer, B. Kitch et al., axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase, Mol. Cell. Biol, vol.11, pp.5016-5031, 1991.

F. C. O'connell, M. , and F. , Laminin-rich extracellular matrix association with mammary epithelial cells suppresses Brca1 expression, Cell Death Differ, vol.7, pp.360-367, 2000.

T. Odorisio, M. Di-salvio, A. Orecchia, G. Di-zenzo, E. Piccinni et al., , 2014.

S. Ogino, J. A. Meyerhardt, M. Cantor, M. Brahmandam, J. W. Clark et al., Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer, Clin. Cancer Res, vol.11, pp.6650-6656, 2005.

K. Ohashi, L. V. Sequist, M. E. Arcila, T. Moran, J. Chmielecki et al., Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1, Proc. Natl, 2012.

, Acad. Sci. U. S. A, vol.109, pp.2127-2133

T. Okawa, C. Z. Michaylira, J. Kalabis, D. B. Stairs, H. Nakagawa et al., The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation, Genes Dev, vol.21, p.2788, 2007.

K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. Mcintyre et al., , vol.324, pp.1457-1461, 2009.

A. F. Olumi, G. D. Grossfeld, S. W. Hayward, P. R. Carroll, T. D. Tlsty et al., , 1999.

A. W. Opipari, H. M. Hu, R. Yabkowitz, and V. M. Dixit, The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity, J. Biol. Chem, vol.267, pp.12424-12427, 1992.

W. H. Organization, I. A. Cancer, and . For-r.-on, Pathology and Genetics of Head and Neck Tumours (IARC), 2005.

A. Orimo, P. B. Gupta, D. C. Sgroi, F. Arenzana-seisdedos, T. Delaunay et al., , 2005.

T. Oskarsson, S. Acharyya, X. H. Zhang, .. Vanharanta, S. Tavazoie et al., Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs, Nat. Med, vol.17, pp.867-874, 2011.

C. H. Österreicher, M. Penz-Österreicher, S. I. Grivennikov, M. Guma, E. K. Koltsova et al., Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver, Proc. Natl. Acad. Sci. U. S. A, vol.108, pp.308-313, 2011.

A. Östman, The tumor microenvironment controls drug sensitivity, Nat. Med, vol.18, pp.1332-1334, 2012.

G. R. Oxnard, V. A. Miller, M. E. Robson, C. G. Azzoli, W. Pao et al., , 2012.

, Screening for germline EGFR T790M mutations through lung cancer genotyping, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, vol.7, pp.1049-1052

B. Ozanne, C. S. Richards, F. Hendler, D. Burns, and B. Gusterson, Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas, J. Pathol, vol.149, pp.9-14, 1986.

B. C. Özdemir, T. Pentcheva-hoang, J. L. Carstens, X. Zheng, C. Wu et al., Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival, Cancer Cell, vol.25, pp.719-734, 2014.

J. D. Paccez, G. J. Vasques, R. G. Correa, J. F. Vasconcellos, K. Duncan et al., , 2013.

J. D. Paccez, K. Duncan, A. Vava, R. G. Correa, T. A. Libermann et al.,

S. Paget, THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST, The Lancet, vol.133, pp.571-573, 1889.

S. I. Pai and W. H. Westra, Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment, Annu. Rev. Pathol, vol.4, pp.49-70, 2009.

F. Pampaloni, E. G. Reynaud, and E. H. Stelzer, The third dimension bridges the gap between cell culture and live tissue, Nat. Rev. Mol. Cell Biol, vol.8, pp.839-845, 2007.

S. Panjarian, R. E. Iacob, S. Chen, J. R. Engen, and T. E. Smithgall, Structure and dynamic regulation of Abl kinases, J. Biol. Chem, vol.288, pp.5443-5450, 2013.

D. Pankova, Y. Chen, M. Terajima, M. J. Schliekelman, B. N. Baird et al., Cancer-Associated Fibroblasts Induce a Collagen Crosslink Switch in Tumor Stroma, Mol. Cancer Res. MCR, vol.14, pp.287-295, 2016.

M. Paolino, A. Choidas, S. Wallner, B. Pranjic, I. Uribesalgo et al., The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells, Nature, vol.507, pp.508-512, 2014.

K. H. Paraiso and K. S. Smalley, Fibroblast-mediated drug resistance in cancer, Biochem. Pharmacol, vol.85, pp.1033-1041, 2013.

A. Parekh, N. S. Ruppender, K. M. Branch, M. K. Sewell-loftin, J. Lin et al., Sensing and modulation of invadopodia across a wide range of rigidities, Biophys. J, vol.100, pp.573-582, 2011.

M. Parri and P. Chiarugi, Rac and Rho GTPases in cancer cell motility control, Cell Commun. Signal. CCS, vol.8, p.23, 2010.

I. Pastushenko, A. Brisebarre, A. Sifrim, M. Fioramonti, T. Revenco et al., Identification of the tumour transition states occurring during EMT, Nature, vol.556, p.463, 2018.

M. J. Paszek, N. Zahir, K. R. Johnson, J. N. Lakins, G. I. Rozenberg et al., Tensional homeostasis and the malignant phenotype, Cancer Cell, vol.8, pp.241-254, 2005.

S. G. Patel and J. P. Shah, TNM staging of cancers of the head and neck: striving for uniformity among diversity, CA. Cancer J. Clin, vol.55, pp.242-258, 2005.

S. Pece and J. S. Gutkind, Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation, J. Biol. Chem, vol.275, pp.41227-41233, 2000.

S. Pece, M. Chiariello, C. Murga, and J. S. Gutkind, , 1999.

, J. Biol. Chem, vol.274, pp.19347-19351

X. Peng, X. Wu, J. E. Druso, H. Wei, A. Y. Park et al., Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice, Proc. Natl. Acad. Sci. U. S. A, vol.105, pp.6638-6643, 2008.

F. Petrelli, K. Borgonovo, and S. Barni, The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials, Target. Oncol, vol.8, pp.173-181, 2013.

M. W. Pickup, J. K. Mouw, and V. M. Weaver, The extracellular matrix modulates the hallmarks of cancer, EMBO Rep, vol.15, pp.1243-1253, 2014.

K. Pietras, T. Sjöblom, K. Rubin, C. Heldin, and A. Ostman, , 2003.

K. Pietras, J. Pahler, G. Bergers, and D. Hanahan, Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting, PLOS Med, vol.5, p.19, 2008.

J. Pignon, J. Bourhis, C. Domenge, and L. Designé, Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data, The Lancet, vol.355, pp.949-955, 2000.

D. J. Pinato, F. A. Mauri, T. Lloyd, V. Vaira, C. Casadio et al., , 2013.

B. R. Pires, A. L. Mencalha, G. M. Ferreira, W. F. De-souza, J. A. Morgado-díaz et al., NF-kappaB Is Involved in the Regulation of, EMT Genes in Breast Cancer Cells. PLoS ONE, vol.12, 2017.

M. L. Poeta, J. Manola, M. A. Goldwasser, A. Forastiere, N. Benoit et al., TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med, vol.357, pp.2552-2561, 2007.

K. Polyak and R. A. Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, Nat. Rev. Cancer, vol.9, pp.265-273, 2009.

O. Pontiggia, R. Sampayo, D. Raffo, A. Motter, R. Xu et al., The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through ?1 integrin, Breast Cancer Res. Treat, vol.133, pp.459-471, 2012.

S. Postel-vinay and A. Ashworth, AXL and acquired resistance to EGFR inhibitors, Nat. Genet, vol.44, pp.835-836, 2012.

J. T. Poterucha, J. N. Johnson, M. Y. Qureshi, P. W. O'leary, P. S. Kamath et al., Magnetic Resonance Elastography -A Novel Technique for Detection of Hepatic Fibrosis and Hepatocellular Carcinoma After the Fontan Operation, Mayo Clin. Proc, vol.90, pp.882-894, 2015.

N. Prenzel, E. Zwick, H. Daub, M. Leserer, R. Abraham et al., EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF, Nature, vol.402, pp.884-888, 1999.

A. Prestipino, A. J. Emhardt, K. Aumann, D. O'sullivan, S. P. Gorantla et al., Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms, Sci. Transl. Med, vol.10, 2018.

S. A. Prigent and W. J. Gullick, Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera, EMBO J, vol.13, pp.2831-2841, 1994.

P. P. Provenzano, K. W. Eliceiri, J. M. Campbell, D. R. Inman, J. G. White et al., , 2006.

P. P. Provenzano, D. R. Inman, K. W. Eliceiri, S. M. Trier, K. et al., , 2008.

P. P. Provenzano, D. R. Inman, K. W. Eliceiri, K. , and P. J. , Matrix density-induced mechanoregulation of breast cell phenotype, signaling, and gene expression through a FAK-ERK linkage, Oncogene, vol.28, pp.4326-4343, 2009.

M. Prunotto, M. Bruschi, P. Gunning, G. Gabbiani, F. Weibel et al., Stable incorporation of ?-smooth muscle actin into stress fibers is dependent on specific tropomyosin isoforms, Cytoskelet. Hoboken NJ, vol.72, pp.257-267, 2015.

A. Puisieux, T. Brabletz, and J. Caramel, Oncogenic roles of EMT-inducing transcription factors, Nat. Cell Biol, vol.16, pp.488-494, 2014.

A. P. Putzke, A. P. Ventura, A. M. Bailey, C. Akture, J. Opoku-ansah et al., Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases, Am. J. Pathol, vol.179, pp.400-410, 2011.

D. Quail, J. , and J. , Microenvironmental regulation of tumor progression and metastasis, 2013.

, Nat. Med, vol.19, pp.1423-1437

M. Quante, S. P. Tu, H. Tomita, T. Gonda, S. S. Wang et al., Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth, Cancer Cell, vol.19, pp.257-272, 2011.

L. Raffaghello and F. Dazzi, Classification and biology of tumour associated stromal cells, Immunol. Lett, vol.168, pp.175-182, 2015.

C. C. Ragin and E. Taioli, Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis, Int. J. Cancer, vol.121, pp.1813-1820, 2007.

J. Raguz, I. Jeric, T. Niault, J. D. Nowacka, S. E. Kuzet et al.,

S. Rahman, Y. Patel, J. Murray, K. V. Patel, R. Sumathipala et al., , 2005.

S. A. Rajasekaran, L. G. Palmer, K. Quan, J. F. Harper, W. J. Ball et al., Na,K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility, Mol. Biol. Cell, vol.12, pp.279-295, 2001.

N. Ramamonjisoa, A. , and E. , Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging, Front. Oncol, vol.7, 2017.

E. B. Rankin, K. C. Fuh, T. E. Taylor, A. J. Krieg, M. Musser et al., AXL is an essential factor and therapeutic target for metastatic ovarian cancer, Cancer Res, vol.70, pp.7570-7579, 2010.

M. Razandi, A. Pedram, S. T. Park, and E. R. Levin, Proximal events in signaling by plasma membrane estrogen receptors, J. Biol. Chem, vol.278, pp.2701-2712, 2003.

K. Rea, P. Pinciroli, M. Sensi, F. Alciato, B. Bisaro et al., Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome, Oncotarget, vol.6, pp.30859-30875, 2015.

P. Reddy, L. Liu, C. Ren, P. Lindgren, K. Boman et al., , 2005.

, Mol. Endocrinol. Baltim. Md, vol.19, pp.2564-2578

A. L. Reed, J. Califano, P. Cairns, W. H. Westra, R. M. Jones et al., High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma, Cancer Res, vol.56, pp.3630-3633, 1996.

A. D. Rhim, P. E. Oberstein, D. H. Thomas, E. T. Mirek, C. F. Palermo et al., Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma, Cancer Cell, vol.25, pp.735-747, 2014.

A. J. Rice, E. Cortes, D. Lachowski, B. C. Cheung, S. A. Karim et al., Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells, vol.6, p.352, 2017.

A. J. Rice, E. Cortes, D. Lachowski, B. C. Cheung, S. A. Karim et al., Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells, vol.6, p.352, 2017.

A. J. Ridley, M. A. Schwartz, K. Burridge, R. A. Firtel, M. H. Ginsberg et al., Cell migration: integrating signals from front to back, Science, vol.302, pp.1704-1709, 2003.

K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu et al., Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, vol.131, pp.1190-1203, 2007.

A. Del-rio, R. Perez-jimenez, R. Liu, P. Roca-cusachs, J. M. Fernandez et al., , 2009.

A. B. Roberts, B. K. Mccune, and M. B. Sporn, TGF-beta: regulation of extracellular matrix, Kidney Int, vol.41, pp.557-559, 1992.

H. P. Rodemann and G. A. Müller, Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis, Am. J. Kidney Dis. Off. J. Natl. Kidney Found, vol.17, pp.684-686, 1991.

G. Rosenblum, P. E. Van-den-steen, S. R. Cohen, J. G. Grossmann, J. Frenkel et al., Insights into the Structure and Domain Flexibility of Full-Length Pro-Matrix Metalloproteinase-9/Gelatinase B. Structure, vol.15, pp.1227-1236, 2007.

C. K. Rosenthal, EGFR probes matrix stiffness, Nat. Cell Biol, vol.19, p.600, 2017.

S. M. Rothenberg and L. W. Ellisen, The molecular pathogenesis of head and neck squamous cell carcinoma, J. Clin. Invest, vol.122, pp.1951-1957, 2012.

R. Grandis, J. Melhem, M. F. Gooding, W. E. Day, R. Holst et al., Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival, J. Natl. Cancer Inst, vol.90, pp.824-832, 1998.

E. Ruoslahti and J. C. Reed, Anchorage dependence, integrins, and apoptosis, Cell, vol.77, pp.477-478, 1994.

B. Rybinski, J. Franco-barraza, and E. Cukierman, The wound healing, chronic fibrosis, and cancer progression triad, Physiol. Genomics, vol.46, pp.223-244, 2014.

P. P. Sainaghi, L. Castello, L. Bergamasco, M. Galletti, P. Bellosta et al., Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor, J. Cell. Physiol, vol.204, pp.36-44, 2005.

T. Saitoh, M. Yamamoto, M. Miyagishi, K. Taira, M. Nakanishi et al., , 2005.

, Immunol. Baltim. Md, vol.174, pp.1507-1512, 1950.

D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit. Rev. Oncol. Hematol, vol.19, pp.183-232, 1995.

M. B. Salt, S. Bandyopadhyay, and F. Mccormick, Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation, Cancer Discov, vol.4, pp.186-199, 2014.

L. B. Saltz, N. J. Meropol, P. J. Loehrer, M. N. Needle, J. Kopit et al., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, J. Clin. Oncol, vol.22, pp.1201-1208, 2004.

M. S. Samuel, J. I. Lopez, E. J. Mcghee, D. R. Croft, D. Strachan et al., , 2011.

R. J. Sanderson and J. A. Ironside, Squamous cell carcinomas of the head and neck, BMJ, vol.325, pp.822-827, 2002.

S. Sano, S. Itami, K. Takeda, M. Tarutani, Y. Yamaguchi et al., Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis, EMBO J, vol.18, pp.4657-4668, 1999.

V. Sanz-moreno, G. Gadea, J. Ahn, H. Paterson, P. Marra et al., Rac activation and inactivation control plasticity of tumor cell movement, Cell, vol.135, pp.510-523, 2008.

F. H. Sarkar, Y. Li, Z. Wang, and D. Kong, Pancreatic cancer stem cells and EMT in drug resistance and metastasis, Minerva Chir, vol.64, pp.489-500, 2009.

R. Sarközi, C. Hauser, S. Noppert, A. Kronbichler, M. Pirklbauer et al., Oncostatin M is a novel inhibitor of TGF-?1-induced matricellular protein expression, Am. J. Physiol. Renal Physiol, vol.301, pp.1014-1025, 2011.

A. Sartore-bianchi, F. Di-nicolantonio, M. Nichelatti, F. Molinari, S. De-dosso et al., Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer, PloS One, vol.4, p.7287, 2009.

T. Sawabu, H. Seno, T. Kawashima, A. Fukuda, Y. Uenoyama et al., Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway, Mol. Carcinog, vol.46, pp.155-164, 2007.

Y. Sawada, M. Tamada, B. J. Dubin-thaler, O. Cherniavskaya, R. Sakai et al., Force sensing by mechanical extension of the Src family kinase substrate p130Cas, Cell, vol.127, pp.1015-1026, 2006.

M. Saxena, S. Liu, B. Yang, C. Hajal, R. Changede et al., EGFR and HER2 Activate Rigidity Sensing Only on Rigid Matrices, Nat. Mater, vol.16, pp.775-781, 2017.

M. Scaltriti, M. Elkabets, and J. Baselga, Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.22, pp.1313-1317, 2016.

R. Schmitz, M. Hansmann, V. Bohle, J. I. Martin-subero, S. Hartmann et al., TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma, J. Exp. Med, vol.206, pp.981-989, 2009.

K. Schönberg, J. Rudolph, M. Vonnahme, S. Parampalli-yajnanarayana, I. Cornez et al., JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms, Cancer Res, vol.75, pp.2187-2199, 2015.

J. Schrader, T. T. Gordon-walker, R. L. Aucott, M. Van-deemter, A. Quaas et al., Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells, Hepatol. Baltim. Md, vol.53, pp.1192-1205, 2011.

R. L. Schroeder, C. L. Stevens, and J. Sridhar, , 2014.

, Mol. Basel Switz, vol.19, pp.15196-15212

P. C. Schuberth, C. Hagedorn, S. M. Jensen, P. Gulati, O. M. Belaunzaran et al., Pre-clinical testing of malignant fibroblast activation proteinspecific re-directed T cells for treatment of pleural mesothelioma, J. Immunother. Cancer, vol.1, p.35, 2013.

M. A. Schwartz, Integrins and Extracellular Matrix in Mechanotransduction, Cold Spring Harb. Perspect. Biol, vol.2, 2010.

G. Seghezzi, S. Patel, C. J. Ren, A. Gualandris, G. Pintucci et al., Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to, Angiogenesis. J. Cell Biol, vol.141, pp.1659-1673, 1998.

K. Seip, K. G. Fleten, A. Barkovskaya, V. Nygaard, M. H. Haugen et al., Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors, Oncotarget, vol.7, 2016.

T. Y. Seiwert, B. Burtness, R. Mehra, J. Weiss, R. Berger et al., Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol, vol.17, pp.956-965, 2016.

A. A. Shafi, M. J. Schiewer, R. De-leeuw, E. Dylgjeri, P. A. Mccue et al., Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response, Eur. Urol. Oncol, vol.1, pp.325-337, 2018.

E. R. Shamir, E. Pappalardo, D. M. Jorgens, K. Coutinho, W. Tsai et al., Twist1-induced dissemination preserves epithelial identity and requires E-cadherin, J. Cell Biol, vol.204, pp.839-856, 2014.

V. K. Shanmugam, S. Mcnish, N. Shara, K. J. Hubley, B. Kallakury et al., Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)), J. Foot Ankle Surg. Off. Publ. Am. Coll. Foot Ankle Surg, vol.52, pp.781-785, 2013.

L. Shao, S. Oshima, B. Duong, R. Advincula, J. Barrera et al., A20 restricts wnt signaling in intestinal epithelial cells and suppresses colon carcinogenesis, PloS One, vol.8, 2013.

Z. M. Shao, M. Nguyen, and S. H. Barsky, Human breast carcinoma desmoplasia is PDGF initiated, Oncogene, vol.19, pp.4337-4345, 2000.

L. Q. Shapiro, E. J. Sherman, N. Riaz, J. Setton, L. Koutcher et al., Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or highdose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC), Oral Oncol, vol.50, pp.947-955, 2014.

C. Sheridan, First Axl inhibitor enters clinical trials, Nat. Biotechnol, vol.31, pp.775-776, 2013.

J. J. Sheu, .. Hua, C. Wan, L. Lin, Y. Lai et al., Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma, Cancer Res, vol.69, pp.2568-2576, 2009.

C. Shi and J. H. Kehrl, TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy, Sci. Signal, vol.3, p.42, 2010.

Y. Shieh, C. Lai, Y. Kao, S. Shiah, Y. Chu et al., Expression of axl in lung adenocarcinoma and correlation with tumor progression, vol.7, pp.1058-1064, 2005.

H. Shimokawa, K. Hiramori, H. Iinuma, S. Hosoda, H. Kishida et al., Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study, J. Cardiovasc. Pharmacol, vol.40, pp.751-761, 2002.

C. G. Da-silva, D. C. Minussi, C. Ferran, and M. Bredel, A20 expressing tumors and anticancer drug resistance, Adv. Exp. Med. Biol, vol.809, pp.65-81, 2014.

L. Simpson, X. He, M. Pins, X. Huang, S. C. Campbell et al.,

, Renal medullary carcinoma and ABL gene amplification, J. Urol, vol.173, pp.1883-1888

A. Singh and J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, Oncogene, vol.29, pp.4741-4751, 2010.

A. B. Singh and R. C. Harris, Autocrine, paracrine and juxtacrine signaling by EGFR ligands, Cell. Signal, vol.17, pp.1183-1193, 2005.

A. Singh, I. Brito, and J. Lammerding, Beyond Tissue Stiffness and Bioadhesivity: Advanced Biomaterials to Model Tumor Microenvironments and Drug Resistance, Trends Cancer, vol.4, pp.281-291, 2018.

D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich et al., , 1987.

W. J. Slichenmyer and D. W. Fry, Anticancer therapy targeting the erbB family of receptor tyrosine kinases, Semin. Oncol, vol.28, pp.67-79, 2001.

S. J. Smeets, M. Van-der-plas, T. B. Schaaij-visser, E. A. Van-veen, J. Van-meerloo et al., Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways, Int. J. Cancer, vol.128, pp.1596-1605, 2011.

R. W. Smits, S. Koljenovi?, J. A. Hardillo, I. Ten-hove, C. A. Meeuwis et al., Resection margins in oral cancer surgery: Room for improvement, Head Neck, vol.38, pp.2197-2203, 2016.

L. H. Sobin, TNM: evolution and relation to other prognostic factors, Semin. Surg. Oncol, vol.21, pp.3-7, 2003.

J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi et al., Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.12, pp.5064-5073, 2006.

S. Song, S. Honjo, J. Jin, S. Chang, A. W. Scott et al., The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemo-resistance in esophageal cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.21, pp.2580-2590, 2015.

S. Sonnylal, X. Shi-wen, P. Leoni, K. Naff, C. S. Van-pelt et al., , vol.62, pp.1523-1532, 2010.

M. L. Sos, K. Michel, T. Zander, J. Weiss, P. Frommolt et al., Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions, J. Clin. Invest, vol.119, pp.1727-1740, 2009.

T. Soussi, S. Kato, P. P. Levy, and C. Ishioka, , 2005.

J. P. Spano, G. Milano, S. Vignot, and D. Khayat, Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer, Crit. Rev. Oncol. Hematol, vol.66, pp.21-30, 2008.

S. A. Spencer, J. Harris, R. H. Wheeler, M. Machtay, C. Schultz et al., Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck, Head Neck, vol.30, pp.281-288, 2008.

D. Srinivasan and R. Plattner, Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells, Cancer Res, vol.66, pp.5648-5655, 2006.

S. Stavrou and S. R. Ross, APOBEC3 Proteins in Viral Immunity, J. Immunol. Baltim. Md, pp.4565-4570, 2015.

P. Storz, H. Döppler, C. Ferran, S. T. Grey, and A. Toker, Functional dichotomy of A20 in apoptotic and necrotic cell death, Biochem. J, vol.387, pp.47-55, 2005.

R. Straussman, T. Morikawa, K. Shee, M. Barzily-rokni, Z. R. Qian et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, vol.487, pp.500-504, 2012.

F. Strutz, H. Okada, C. W. Lo, T. Danoff, R. L. Carone et al., , 1995.

, Identification and characterization of a fibroblast marker: FSP1, J. Cell Biol, vol.130, pp.393-405

F. Strutz, M. Zeisberg, B. Hemmerlein, B. Sattler, K. Hummel et al., , 2000.

, Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation, Kidney Int, vol.57, pp.1521-1538

T. J. Stuhlmiller, S. M. Miller, J. S. Zawistowski, K. Nakamura, A. S. Beltran et al., Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains, Cell Rep, vol.11, pp.390-404, 2015.

R. Stupp, M. E. Hegi, T. Gorlia, S. C. Erridge, J. Perry et al., Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, Lancet Oncol, vol.15, pp.1100-1108, 2014.

H. Sugimoto, T. M. Mundel, M. W. Kieran, and R. Kalluri, Identification of fibroblast heterogeneity in the tumor microenvironment, Cancer Biol. Ther, vol.5, pp.1640-1646, 2006.

H. Sunada, B. E. Magun, J. Mendelsohn, and C. L. Macleod, Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation, Proc. Natl. Acad. Sci. U. S. A, vol.83, pp.3825-3829, 1986.

L. Sweeny, Z. Liu, W. Lancaster, J. Hart, Y. E. Hartman et al., Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor, The Laryngoscope, vol.122, pp.1539-1544, 2012.

S. Takahashi, D. Hashimoto, E. Hayase, R. Ogasawara, H. Ohigashi et al., Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease, Blood, vol.131, pp.2074-2085, 2018.

K. Takezawa, V. Pirazzoli, M. E. Arcila, C. A. Nebhan, X. Song et al., HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation, Cancer Discov, vol.2, pp.922-933, 2012.

, uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis, Sci. Transl. Med

L. Vereecke, S. Vieira-silva, T. Billiet, J. H. Van-es, C. Mc-guire et al., A20 controls intestinal homeostasis through cellspecific activities, Nat. Commun, vol.5, p.5103, 2014.

A. Verma, S. L. Warner, H. Vankayalapati, D. J. Bearss, and S. Sharma, Targeting Axl and Mer kinases in cancer, Mol. Cancer Ther, vol.10, pp.1763-1773, 2011.

J. B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer, N. Engl. J. Med, vol.359, pp.1116-1127, 2008.

S. Verstovsek, H. Kantarjian, R. A. Mesa, A. D. Pardanani, J. Cortes-franco et al., Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, N. Engl. J. Med, vol.363, pp.1117-1127, 2010.

L. Verstrepen, K. Verhelst, G. Van-loo, I. Carpentier, S. C. Ley et al., Expression, biological activities and mechanisms of action of A20 (TNFAIP3), Biochem. Pharmacol, vol.80, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00637146

P. Vineis, Cancer as an evolutionary process at the cell level: an epidemiological perspective, Carcinogenesis, vol.24, pp.1-6, 2003.

R. Virchow, Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre, 1859.

K. E. De-visser, A. Eichten, and L. M. Coussens, Paradoxical roles of the immune system during cancer development, Nat. Rev. Cancer, vol.6, pp.24-37, 2006.

E. E. Vokes and R. R. Weichselbaum, Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.8, pp.911-934, 1990.

E. E. Vokes, A. M. Awan, and R. R. Weichselbaum, Radiotherapy with concomitant chemotherapy for head and neck cancer, Hematol. Oncol. Clin. North Am, vol.5, pp.753-767, 1991.

E. E. Vokes, R. R. Weichselbaum, S. M. Lippman, and W. K. Hong, , 1993.

, Engl. J. Med, vol.328, pp.184-194

M. Vouri, Q. An, M. Birt, G. J. Pilkington, and S. Hafizi, Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells, Oncotarget, vol.6, pp.16183-16197, 2015.

V. Vukovic and I. F. Tannock, Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan, Br. J. Cancer, vol.75, pp.1167-1172, 1997.

K. Vuoriluoto, H. Haugen, S. Kiviluoto, J. Mpindi, J. Nevo et al., Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer, Oncogene, vol.30, pp.1436-1448, 2011.

Z. Wang and G. Ouyang, Periostin: A Bridge between Cancer Stem Cells and Their Metastatic Niche, Cell Stem Cell, vol.10, pp.111-112, 2012.

C. Wang, H. Jin, N. Wang, S. Fan, Y. Wang et al.,

, Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3?/?-catenin Signaling, Theranostics, vol.6, pp.1205-1219

C. C. Wang, P. H. Blitzer, and H. D. Suit, Twice-a-day radiation therapy for cancer of the head and neck, Cancer, vol.55, pp.2100-2104, 1985.

J. Wang, Q. Wei, X. Wang, S. Tang, H. Liu et al., Transition to resistance: An unexpected role of the EMT in cancer chemoresistance, Genes Dis, vol.3, pp.3-6, 2016.

L. S. Wang, A. Lo, J. Scholler, J. Sun, R. S. Majumdar et al., Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity Without Severe Toxicity, Cancer Immunol. Res, vol.2, pp.154-166, 2014.

W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto et al., , 2009.

W. Wang, A. K. Erbe, J. A. Hank, Z. S. Morris, and P. M. Sondel, NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front. Immunol, vol.6, 2015.

W. Wang, Y. Chien, Y. Wong, Y. Lin, and J. Lin, , 2012.

S. Warnakulasuriya, Global epidemiology of oral and oropharyngeal cancer, Oral Oncol, vol.45, pp.309-316, 2009.

M. Wartenberg, F. C. Ling, M. Müschen, F. Klein, H. Acker et al., Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species, 2003.

, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol, vol.17, pp.503-505

A. L. Watne, Treatment alternatives. Head and neck cancers, Cancer, vol.54, pp.2673-2681, 1984.

W. B. Weglicki, J. H. Kramer, C. F. Spurney, J. J. Chmielinska, and I. T. Mak, The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction. Can, J. Physiol. Pharmacol, vol.90, pp.1145-1149, 2012.

S. C. Wei, L. Fattet, J. H. Tsai, Y. Guo, V. H. Pai et al., Matrix stiffness drives Epithelial-Mesenchymal Transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway, Nat. Cell Biol, vol.17, pp.678-688, 2015.

J. M. Weiss, J. E. Grilley-olson, A. M. Deal, J. P. Zevallos, B. S. Chera et al., Cancer, vol.124, pp.2986-2992, 2018.

Z. Werb, ECM and Cell Surface Proteolysis: Regulating Cellular Ecology, Cell, vol.91, pp.439-442, 1997.

D. L. Wheeler, E. F. Dunn, and P. M. Harari, Understanding resistance to EGFR inhibitorsimpact on future treatment strategies, Nat. Rev. Clin. Oncol, vol.7, pp.493-507, 2010.

M. J. Wheelock, Y. Shintani, M. Maeda, Y. Fukumoto, J. et al., Cadherin switching, 2008.

, J. Cell Sci, vol.121, pp.727-735

T. Whiteside, The tumor microenvironment and its role in promoting tumor growth, Oncogene, vol.27, pp.5904-5912, 2008.

S. P. Whitman, J. Kohlschmidt, K. Maharry, S. Volinia, K. Mrózek et al., GAS6 expression identifies high-risk adult AML patients: potential implications for therapy, Leukemia, vol.28, pp.1252-1258, 2014.

E. S. Wijelath, S. Rahman, M. Namekata, J. Murray, T. Nishimura et al., synergism. Circ. Res, vol.99, pp.853-860, 2006.

C. Wilson, X. Ye, T. Pham, E. Lin, S. Chan et al., AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs, Cancer Res, vol.74, pp.5878-5890, 2014.

T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton et al., Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, vol.487, pp.505-509, 2012.

B. S. Wiseman and Z. Werb, Stromal effects on mammary gland development and breast cancer, Science, vol.296, pp.1046-1049, 2002.

K. Wolf, M. Te-lindert, M. Krause, S. Alexander, J. Te-riet et al., Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force, J. Cell Biol, vol.201, pp.1069-1084, 2013.

M. Won, K. A. Park, H. S. Byun, K. Sohn, Y. Kim et al., Novel anti-apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation, Cell Death Differ, vol.17, pp.1830-1841, 2010.

G. Wu, Z. Ma, Y. Cheng, W. Hu, C. Deng et al., Targeting Gas6/TAM in cancer cells and tumor microenvironment, Mol. Cancer, vol.17, 2018.

X. Wu, X. Chen, Q. Zhou, P. Li, B. Yu et al., , 2013.

Y. Wu, C. Zhou, C. Hu, J. Feng, S. Lu et al.,

T. Wynn, Cellular and molecular mechanisms of fibrosis, J. Pathol, vol.214, pp.199-210, 2008.

H. Xia, X. Dai, H. Yu, S. Zhou, Z. Fan et al., EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy, Cell Death Dis, vol.9, p.269, 2018.

X. Xian, S. Gopal, and J. R. Couchman, Syndecans as receptors and organizers of the extracellular matrix, Cell Tissue Res, vol.339, pp.31-46, 2010.

M. Xie, L. Zhang, C. He, F. Xu, J. Liu et al., Activation of notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells, J. Cell. Biochem, vol.113, pp.1501-1513, 2012.

T. Xie, Y. Wang, N. Deng, G. Huang, F. Taghavifar et al., Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis, Cell Rep, vol.22, pp.3625-3640, 2018.

M. Xu, S. Chan, A. Liu, K. Wong, S. Fan et al.,

M. B. Yaffe, Phosphotyrosine-binding domains in signal transduction, Nat. Rev. Mol. Cell Biol, vol.3, pp.177-186, 2002.

Y. Yamano, K. Uzawa, K. Saito, D. Nakashima, A. Kasamatsu et al., Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma, Int. J. Cancer, vol.126, pp.437-449, 2010.

N. Yamashita, E. Tokunaga, M. Iimori, Y. Inoue, K. Tanaka et al., Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin With Regard to Invasion and Metastasis of Breast Cancer, Clin. Breast Cancer, vol.18, pp.1003-1009, 2018.

T. Yamauchi, K. Ueki, K. Tobe, H. Tamemoto, N. Sekine et al., Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone, Nature, vol.390, pp.91-96, 1997.

J. Yang and R. A. Weinberg, Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis, Dev. Cell, vol.14, pp.818-829, 2008.

B. Yang, Z. Z. Lieu, H. Wolfenson, F. M. Hameed, A. D. Bershadsky et al., , 2016.

, Mechanosensing Controlled Directly by Tyrosine Kinases, Nano Lett, vol.16, pp.5951-5961

C. Yang, W. Zang, Z. Tang, Y. Ji, R. Xu et al., , 2018.

, /TNFAIP3 Regulates the DNA Damage Response and Mediates Tumor Cell Resistance to DNA-Damaging Therapy, Cancer Res, vol.78, pp.1069-1082

J. Yang, S. A. Mani, J. L. Donaher, S. Ramaswamy, R. A. Itzykson et al., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis, Cell, vol.117, pp.927-939, 2004.

L. Yang, C. Lin, and Z. Liu, P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin, Cell, vol.127, pp.139-155, 2006.

L. Yang, A. Achreja, T. Yeung, L. S. Mangala, D. Jiang et al., Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth, Cell Metab, vol.24, pp.685-700, 2016.

Q. Yang, J. Huang, Q. Wu, Y. Cai, L. Zhu et al., Br. J. Cancer, vol.110, pp.1958-1967, 2014.

Z. Yao, S. Fenoglio, D. C. Gao, M. Camiolo, B. Stiles et al.,

Y. Yarden, The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities, Eur. J. Cancer, vol.37, pp.3-8, 2001.

S. J. Yarwood and J. R. Woodgett, Extracellular matrix composition determines the transcriptional response to epidermal growth factor receptor activation, Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.4472-4477, 2001.

R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu et al., Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.11, pp.8686-8698, 2005.

A. Y. Ye, J. H. Hay, J. J. Laskin, J. S. Wu, and C. C. Ho, Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab, J. Cancer Res. Ther, vol.9, pp.607-612, 2013.

X. Ye, Y. Li, S. Stawicki, S. Couto, J. Eastham-anderson et al., An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies, Oncogene, vol.29, pp.5254-5264, 2010.

D. H. Yeh, S. Tam, K. Fung, S. D. Macneil, J. Yoo et al.,

, Transoral robotic surgery vs. radiotherapy for management of oropharyngeal squamous cell carcinoma -A systematic review of the literature, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br

. Assoc, Surg. Oncol, vol.41, pp.1603-1614

M. Yilmaz and G. Christofori, EMT, the cytoskeleton, and cancer cell invasion, Cancer Metastasis Rev, vol.28, pp.15-33, 2009.

Z. A. Yochum, J. Cades, H. Wang, S. Chatterjee, B. W. Simons et al., , 2019.

K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo et al., Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab, Sci. Transl. Med, vol.3, pp.99-86, 2011.

H. Yuen, C. M. Mccrudden, Y. Huang, J. M. Tham, X. Zhang et al., TAZ Expression as a Prognostic Indicator in Colorectal Cancer, PLOS ONE, vol.8, p.54211, 2013.

C. Yun, T. J. Boggon, Y. Li, M. S. Woo, H. Greulich et al., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity, Cancer Cell, vol.11, pp.217-227, 2007.

U. Zaleska-dorobisz, K. Kaczorowski, A. Pawlu?, A. Puchalska, and M. Inglot, Ultrasound elastography -review of techniques and its clinical applications, Adv. Clin. Exp. Med. Off. Organ Wroclaw Med. Univ, vol.23, pp.645-655, 2014.

M. G. Zampino, E. Magni, M. C. Leonardi, L. Santoro, E. Petazzi et al., , 2011.

F. Zanconato, M. Cordenonsi, and S. Piccolo, YAP/TAZ at the Roots of Cancer, Cancer Cell, vol.29, pp.783-803, 2016.

N. Zebda, O. Dubrovskyi, and K. G. Birukov, Focal adhesion kinase regulation of mechanotransduction and its impact on endothelial cell functions, Microvasc. Res, vol.83, pp.71-81, 2012.

A. Zehender, J. Huang, A. Györfi, A. Matei, T. Trinh-minh et al., The tyrosine phosphatase SHP2 controls TGF?-induced STAT3 signaling to regulate fibroblast activation and fibrosis, Nat. Commun, vol.9, p.3259, 2018.

C. Zeltz and D. Gullberg, The integrin-collagen connection--a glue for tissue repair?, J. Cell Sci, vol.129, pp.653-664, 2016.

G. Zhang, X. Kong, M. Wang, H. Zhao, S. Han et al., AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma, Oncol. Lett, vol.15, pp.1900-1906, 2018.

J. Zhang, D. He, M. Zajac-kaye, and S. N. Hochwald, A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells, Cell Cycle, vol.13, pp.3143-3149, 2014.

W. Zhang, Y. Zhu, H. Yang, Q. Wang, X. Wang et al., , 2015.

X. Zhang, Z. Zhang, Q. Zhang, Q. Zhang, P. Sun et al., , p.1, 2018.

Y. Zhang, P. G. Knyazev, Y. V. Cheburkin, K. Sharma, Y. P. Knyazev et al., AXL is a potential target for therapeutic intervention in breast cancer progression, Cancer Res, vol.68, pp.1905-1915, 2008.

Z. Zhang, J. C. Lee, L. Lin, V. Olivas, V. Au et al., Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer, Nat. Genet, vol.44, pp.852-860, 2012.

B. Zhao, X. Wei, W. Li, R. S. Udan, Q. Yang et al., Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control, Genes Dev, vol.21, pp.2747-2761, 2007.

R. Zhao, B. Y. Choi, M. Lee, A. M. Bode, D. et al., Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer, EBioMedicine, vol.8, pp.30-39, 2016.

Q. Zhou, H. Wang, D. M. Schwartz, M. Stoffels, Y. H. Park et al., Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease, Nat. Genet, vol.48, pp.67-73, 2016.

J. Zuo, W. Zhu, M. Li, X. Li, H. Yi et al., Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin, J. Cell. Biochem, vol.112, pp.2508-2517, 2011.

, Drugs Approved for Head and Neck Cancer

J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell et al., Stat3 as an Oncogene, Cell, vol.98, issue.3, pp.295-303, 1999.

V. M. Chen, R. Shelke, A. Nyström, N. Laver, J. F. Sampson et al., Collagen VII deficient mice show morphologic and histologic corneal changes that phenotypically mimic human dystrophic epidermolysis bullosa of the eye, Exp. Eye Res, vol.175, pp.133-174, 2018.

R. J. Cho, L. B. Alexandrov, N. Y. Den-breems, V. S. Atanasova, M. Farshchian et al., APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa

, Sci. Transl. Med, vol.10, issue.455, 2018.

D. Rosario, M. Tsai, H. Dasanu, and C. A. , Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis, J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract, vol.24, issue.3, pp.226-234, 2018.

J. L. Depry, K. B. Reed, R. H. Cook-norris, and J. D. Brewer, Iatrogenic immunosuppression and cutaneous malignancy, Clin. Dermatol, vol.29, issue.6, pp.602-615, 2011.

N. Do, S. Willenborg, B. Eckes, C. Jüngst, G. Sengle et al., Myeloid Cell-Restricted, p.3

, Signaling Controls a Cell-Autonomous Antifibrotic Repair Program, J. Immunol. Baltim. Md, vol.201, issue.2, pp.663-74, 1950.

J. Fine, L. B. Johnson, M. Weiner, K. Li, and C. Suchindran, Epidermolysis bullosa and the risk of lifethreatening cancers: the National EB Registry experience, J. Am. Acad. Dermatol, vol.60, issue.2, pp.203-214, 1986.

M. C. Föll, M. Fahrner, C. Gretzmeier, K. Thoma, M. L. Biniossek et al., Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas, Matrix Biol. J. Int. Soc. Matrix Biol, vol.66, pp.1-21, 2018.

A. Fritsch, S. Loeckermann, J. S. Kern, A. Braun, M. R. Bösl et al., A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy

, J. Clin. Invest, vol.118, issue.5, pp.1669-79, 2008.

L. Guerra, T. Odorisio, G. Zambruno, and D. Castiglia, Stromal microenvironment in type VII collagendeficient skin: The ground for squamous cell carcinoma development, Matrix Biol. J. Int. Soc. Matrix Biol, vol.63, pp.1-10, 2017.

H. I. Hurwitz, N. Uppal, S. A. Wagner, J. C. Bendell, J. T. Beck et al., Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed, J. Clin. Oncol, vol.33, issue.34, pp.4039-4086, 2015.

J. Huynh, N. Etemadi, F. Hollande, M. Ernst, and M. Buchert, The JAK/STAT3 axis: A comprehensive drug target for solid malignancies, Semin. Cancer Biol, vol.45, pp.13-22, 2017.

L. Intong and D. F. Murrell, Inherited epidermolysis bullosa: new diagnostic criteria and classification

, Clin. Dermatol, vol.30, issue.1, pp.70-77, 2012.

M. Kim and D. F. Murrell, Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa, Eur. J. Dermatol. EJD, vol.25, issue.1, pp.30-32, 2015.

Z. Kopecki, R. M. Arkell, X. L. Strudwick, M. Hirose, R. J. Ludwig et al., Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita, J. Pathol, vol.225, issue.3, pp.401-414, 2011.

T. Kühl, M. Mezger, I. Hausser, R. Handgretinger, L. Bruckner-tuderman et al., High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa, Mol. Ther. J. Am. Soc. Gene Ther, vol.23, issue.8, pp.1368-79, 2015.

V. Küttner, C. Mack, C. Gretzmeier, L. Bruckner-tuderman, and J. Dengjel, Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity, J. Invest. Dermatol, vol.134, issue.9, pp.2381-2390, 2014.

S. Kuzet and C. Gaggioli, Fibroblast activation in cancer: when seed fertilizes soil, Cell Tissue Res, vol.365, issue.3, pp.607-626, 2016.

H. Lee, A. Herrmann, J. Deng, M. Kujawski, G. Niu et al., Persistently Activated Stat3 Maintains Constitutive NF-?B Activity in Tumors, Cancer Cell, vol.15, issue.4, pp.283-93, 2009.

C. P. Lim, T. Phan, I. J. Lim, and X. Cao, Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration, Oncogene, vol.25, issue.39, pp.5416-5441, 2006.

E. Macias, D. Rao, and J. Digiovanni, Role of stat3 in skin carcinogenesis: insights gained from relevant mouse models, J. Skin Cancer, vol.2013, p.684050, 2013.

V. R. Mittapalli, J. Madl, S. Löffek, D. Kiritsi, J. S. Kern et al., Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression, Cancer Res, vol.76, issue.4, pp.940-51, 2016.

Y. Ng, C. Pourreyron, J. C. Salas-alanis, J. Dayal, R. Cepeda-valdes et al.,

A. Nyström, O. Bornert, T. Kühl, C. Gretzmeier, K. Thriene et al., Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa, Proc. Natl. Acad. Sci. U

S. , , vol.115, pp.705-719, 2018.

A. Nyström and L. Bruckner-tuderman, Injury-and inflammation-driven skin fibrosis: The paradigm of epidermolysis bullosa, Matrix Biol. J. Int. Soc. Matrix Biol, pp.547-60, 2018.

A. Nyström, K. Thriene, V. Mittapalli, J. S. Kern, D. Kiritsi et al., Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms, EMBO Mol. Med, vol.7, issue.9, pp.1211-1239, 2015.

A. Nyström, D. Velati, V. R. Mittapalli, A. Fritsch, J. S. Kern et al., Collagen VII plays a dual role in wound healing, J. Clin. Invest, vol.123, issue.8, pp.3498-509, 2013.

T. Odorisio, D. Salvio, M. Orecchia, A. , D. Zenzo et al., Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-? signalling in modifying disease severity, Hum. Mol. Genet, vol.23, issue.15, pp.3907-3929, 2014.

A. Prestipino, A. J. Emhardt, K. Aumann, D. O'sullivan, S. P. Gorantla et al., Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms, Sci. Transl. Med, vol.10, issue.429, 2018.

S. Sano, S. Itami, K. Takeda, M. Tarutani, Y. Yamaguchi et al., Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis, EMBO J, vol.18, issue.17, pp.4657-68, 1999.

R. Sarközi, C. Hauser, S. Noppert, A. Kronbichler, M. Pirklbauer et al., Oncostatin M is a novel inhibitor of TGF-?1-induced matricellular protein expression, Am. J. Physiol. Renal Physiol, vol.301, issue.5, pp.1014-1025, 2011.

K. Schönberg, J. Rudolph, M. Vonnahme, P. Yajnanarayana, S. Cornez et al., Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms, Cancer Res, vol.75, issue.11, pp.2187-99, 2015.

T. Y. Seiwert, B. Burtness, R. Mehra, J. Weiss, R. Berger et al., Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol, vol.17, issue.7, pp.956-65, 2016.

V. K. Shanmugam, S. Mcnish, N. Shara, K. J. Hubley, B. Kallakury et al., Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)), J. Foot Ankle Surg. Off. Publ. Am. Coll. Foot Ankle Surg, vol.52, issue.6, pp.781-786, 2013.

S. Stavrou and S. R. Ross, APOBEC3 Proteins in Viral Immunity, J. Immunol. Baltim. Md, vol.195, issue.10, pp.4565-70, 1950.

S. Takahashi, D. Hashimoto, E. Hayase, R. Ogasawara, H. Ohigashi et al., Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease, Blood, vol.131, issue.18, pp.2074-85, 2018.

K. Thriene, B. A. Grüning, O. Bornert, A. Erxleben, J. Leppert et al., Combinatorial Omics Analysis Reveals Perturbed Lysosomal Homeostasis in Collagen VII-deficient Keratinocytes, Mol. Cell. Proteomics MCP, vol.17, issue.4, pp.565-79, 2018.

S. Tilborghs, J. Corthouts, Y. Verhoeven, D. Arias, C. Rolfo et al., The role of Nuclear Factorkappa B signaling in human cervical cancer, Crit. Rev. Oncol. Hematol, vol.120, pp.141-50, 2017.

M. Vanden-oever, D. Muldoon, W. Mathews, R. Mcelmurry, and J. Tolar, miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa, J. Invest. Dermatol, vol.136, issue.10, pp.2013-2034, 2016.

S. Verstovsek, H. Kantarjian, R. A. Mesa, A. D. Pardanani, J. Cortes-franco et al., Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, N. Engl. J. Med, vol.363, issue.12, pp.1117-1144, 2010.

A. Zehender, J. Huang, A. Györfi, A. Matei, T. Trinh-minh et al., The tyrosine phosphatase SHP2 controls TGF?-induced STAT3 signaling to regulate fibroblast activation and fibrosis, Nat. Commun, vol.9, issue.1, p.3259, 2018.

, Antibodies Antibodies against STAT3 (#9139; 1/1000), vol.2, p.3672

, /500), vimentin (#5741) were purchased from Cell Signaling (Cell SignalingTechnology, Beverly MA), ?-tubulin from sigma (T4026, vol.1, p.416, 2101.

N. F. Boyd, H. Guo, L. J. Martin, L. Sun, J. Stone et al., Mammographic density and the risk and detection of breast cancer, N Engl J Med, vol.356, pp.227-263, 2007.

R. Navab, D. Strumpf, B. Bandarchi, C. Q. Zhu, M. Pintilie et al., Prognostic geneexpression signature of carcinoma-associated fibroblasts in non-small cell lung cancer, Proc Natl Acad Sci U S A, vol.108, pp.7160-7165, 2011.

M. Shi, D. H. Yu, Y. Chen, C. Y. Zhao, J. Zhang et al., Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance, World J Gastroenterol, vol.18, pp.840-846, 2012.

Y. Takahashi, G. Ishii, T. Taira, S. Fujii, S. Yanagi et al., Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients, J Thorac Oncol, vol.6, pp.1460-1467, 2011.

N. A. Bhowmick, E. G. Neilson, and H. L. Moses, Stromal fibroblasts in cancer initiation and progression, Nature, vol.432, pp.332-339, 2004.

F. Calvo and E. Sahai, Cell communication networks in cancer invasion, Curr Opin Cell Biol, vol.23, pp.621-630, 2011.

R. Kalluri and M. Zeisberg, Fibroblasts in cancer, Nat Rev Cancer, vol.6, pp.392-401, 2006.

P. Lu, V. M. Weaver, and Z. Werb, The extracellular matrix: a dynamic niche in cancer progression, J Cell Biol, vol.196, pp.395-406, 2012.

J. Albrengues, I. Bourget, C. Pons, V. Butet, P. Hofman et al., LIF mediates proinvasive activation of stromal fibroblasts in cancer, Cell Rep, vol.7, pp.1664-78, 2014.

V. Sanz-moreno, C. Gaggioli, M. Yeo, J. Albrengues, F. Wallberg et al., ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma, Cancer Cell, vol.20, pp.229-274, 2011.

M. S. Diamond, D. E. Staunton, S. D. Marlin, and T. A. Springer, Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation, Cell, vol.65, pp.961-71, 1991.

L. R. Languino, A. Duperray, K. J. Joganic, M. Fornaro, G. B. Thornton et al., Regulation of leukocyteendothelium interaction and leukocyte transendothelial Oncotarget 1318 www.impactjournals.com/oncotarget migration by intercellular adhesion molecule 1-fibrinogen recognition, Proc Natl Acad Sci U S A, vol.92, pp.1505-1514, 1995.

M. W. Makgoba, M. E. Sanders, G. Luce, G. E. Dustin, M. L. Springer et al., ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells, Nature, vol.331, pp.86-94, 1988.

S. D. Marlin and T. A. Springer, Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte functionassociated antigen 1 (LFA-1), Cell, vol.51, pp.813-822, 1987.

S. E. D'souza, V. J. Byers-ward, E. E. Gardiner, H. Wang, and S. S. Sung, Identification of an active sequence within the first immunoglobulin domain of intercellular cell adhesion molecule-1 (ICAM-1) that interacts with fibrinogen, J Biol Chem, vol.271, pp.24270-24277, 1996.

D. L. Simmons, The role of ICAM expression in immunity and disease, Cancer Surv, vol.24, pp.141-55, 1995.

S. Hua, Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies, Front Pharmacol, vol.4, p.127, 2013.

T. N. Ramos, D. C. Bullard, and S. R. Barnum, ICAM-1: isoforms and phenotypes, J Immunol, vol.192, pp.4469-74, 2014.

A. K. Hubbard and R. Rothlein, Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades, Free Radic Biol Med, vol.28, pp.1379-86, 2000.

S. J. Lee, J. Y. Park, J. Hou, and E. N. Benveniste, Transcriptional regulation of the intercellular adhesion molecule-1 gene by proinflammatory cytokines in human astrocytes, Glia, vol.25, pp.21-32, 1999.

K. A. Roebuck and A. Finnegan, Regulation of intercellular adhesion molecule-1 (CD54) gene expression, J Leukoc Biol, vol.66, pp.876-88, 1999.

P. D. King, E. T. Sandberg, A. Selvakumar, P. Fang, A. L. Beaudet et al., Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing, J Immunol, vol.154, pp.6080-93, 1995.

O. Robledo, A. Papaioannou, B. Ochietti, C. Beauchemin, D. Legault et al., ICAM-1 isoforms: specific activity and sensitivity to cleavage by leukocyte elastase and cathepsin G, Eur J Immunol, vol.33, pp.1351-60, 2003.

N. K. Van-den-engel, E. Heidenthal, A. Vinke, H. Kolb, and S. Martin, Circulating forms of intercellular adhesion molecule (ICAM)-1 in mice lacking membranous ICAM-1, Blood, vol.95, pp.1350-1355, 2000.

K. Maeda, S. M. Kang, T. Sawada, Y. Nishiguchi, M. Yashiro et al., Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer, Oncol Rep, vol.9, pp.511-515, 2002.

L. Taglia, D. Matusiak, K. A. Matkowskyj, and R. V. Benya, Gastrinreleasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase, Am J Physiol Gastrointest Liver Physiol, vol.292, pp.182-90, 2007.

V. S. Schellerer, M. Langheinrich, W. Hohenberger, R. S. Croner, S. Merkel et al., Tumorassociated fibroblasts isolated from colorectal cancer tissues exhibit increased ICAM-1 expression and affinity for monocytes, Oncol Rep, vol.31, pp.255-61, 2014.

J. Albrengues, T. Bertero, E. Grasset, S. Bonan, M. Maiel et al., Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts, Nat Commun, vol.6, p.10204, 2015.

S. Hooper, C. Gaggioli, and E. Sahai, A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion, Br J Cancer, vol.102, pp.392-402, 2010.

T. A. Wynn and T. R. Ramalingam, Mechanisms of fibrosis: therapeutic translation for fibrotic disease, Nat Med, vol.18, pp.1028-1068, 2012.

D. Wever, O. , V. Bockstal, M. Mareel, M. Hendrix et al., Carcinoma-associated fibroblasts provide operational flexibility in metastasis, Semin Cancer Biol, vol.25, pp.33-46, 2014.

R. W. Tilghman and R. L. Hoover, The Src-cortactin pathway is required for clustering of E-selectin and ICAM-1 in endothelial cells, FASEB J, vol.16, pp.1257-1266, 2002.

Q. Wang, G. R. Pfeiffer, and W. A. Gaarde, Activation of SRC tyrosine kinases in response to ICAM-1 ligation in pulmonary microvascular endothelial cells, J Biol Chem, vol.278, pp.47731-47774, 2003.

D. R. Croft and M. F. Olson, Conditional regulation of a ROCKestrogen receptor fusion protein, Methods Enzymol, vol.406, pp.541-53, 2006.

M. Horie, A. Saito, Y. Yamauchi, Y. Mikami, M. Sakamoto et al., Histamine induces human lung fibroblastmediated collagen gel contraction via histamine H1 receptor, Exp Lung Res, vol.40, pp.222-258, 2014.

L. M. Coussens and Z. Werb, Inflammation and cancer, Nature, vol.420, pp.860-867, 2002.

N. Erez, M. Truitt, P. Olson, A. St, and D. Hanahan, Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner, Cancer Cell, vol.17, pp.135-182, 2010.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.11, pp.127-136, 2011.

S. Etienne, P. Adamson, J. Greenwood, A. D. Strosberg, S. Cazaubon et al., ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells, J Immunol, vol.161, pp.5755-61, 1998.

P. W. Thompson, A. M. Randi, and A. J. Ridley, Intercellular adhesion molecule (ICAM)-1, but not ICAM-2, activates RhoA and stimulates c-fos and rhoA transcription in endothelial cells, J Immunol, vol.169, pp.1007-1020, 2002.

F. Calvo, N. Ege, A. Grande-garcia, S. Hooper, R. P. Jenkins et al., Mechanotransduction and YAPdependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts, Nat Cell Biol, 2013.

M. Hu, C. P. Han, X. Cai, G. Q. Liu, G. et al., Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis, J Pharmacol Exp Ther, vol.351, pp.87-95, 2014.

Y. Yan, L. Ma, X. Zhou, M. Ponnusamy, J. Tang et al., Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis, Kidney Int, vol.89, pp.68-81, 2016.

J. S. Hayflick, P. Kilgannon, and W. M. Gallatin, The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions, Immunol Res, vol.17, pp.313-340, 1998.

M. L. Dustin and T. A. Springer, Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells, J Cell Biol, vol.107, pp.321-352, 1988.

A. R. De-fougerolles, S. A. Stacker, R. Schwarting, and T. A. Springer, Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1, J Exp Med, vol.174, pp.253-67, 1991.

A. R. De-fougerolles, M. S. Diamond, and T. A. Springer, Heterogenous glycosylation of ICAM-3 and lack of interaction with Mac-1 and p150,95, Eur J Immunol, vol.25, pp.1008-1020, 1995.

C. Sadhu, B. Lipsky, H. P. Erickson, J. Hayflick, K. O. Dick et al., LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids, Cell Adhes Commun, vol.2, pp.429-469, 1994.

D. Alexiou, A. J. Karayiannakis, K. N. Syrigos, A. Zbar, E. Sekara et al., Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients, Am J Gastroenterol, vol.98, pp.478-85, 2003.

A. Grothey, P. Heistermann, S. Philippou, and R. Voigtmann, Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage, Br J Cancer, vol.77, pp.801-808, 1998.

R. Harning, E. Mainolfi, J. C. Bystryn, M. Henn, V. J. Merluzzi et al., Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma, Cancer Res, vol.51, pp.5003-5008, 1991.

B. Nakata, T. Hori, T. Sunami, Y. Ogawa, M. Yashiro et al., Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer, Clin Cancer Res, vol.6, pp.1175-1184, 2000.

Y. Shimizu, M. Minemura, T. Tsukishiro, Y. Kashii, M. Miyamoto et al., Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis, Hepatology, vol.22, pp.525-556, 1995.

G. J. Zhang and I. Adachi, Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis, Int J Oncol, vol.14, pp.71-78, 1999.

E. C. Lessey-morillon, L. D. Osborne, E. Monaghan-benson, C. Guilluy, E. T. O'brien et al., The RhoA guanine nucleotide exchange factor, LARG, mediates ICAM-1-dependent mechanotransduction in endothelial cells to stimulate transendothelial migration, J Immunol, vol.192, pp.3390-3398, 2014.

Z. Liu, N. J. Sniadecki, and C. S. Chen, Mechanical Forces in Endothelial Cells during Firm Adhesion and Early Transmigration of Human Monocytes, Cell Mol Bioeng, vol.3, pp.50-59, 2010.

T. D. Ross, B. G. Coon, S. Yun, N. Baeyens, K. Tanaka et al.,

, Curr Opin Cell Biol, vol.25, pp.613-621, 2013.

E. H. Danen, J. Van-rheenen, W. Franken, S. Huveneers, P. Sonneveld et al., Integrins control motile strategy through a Rho-cofilin pathway, J Cell Biol, vol.169, pp.515-541, 2005.

C. Gaggioli, S. Hooper, C. Hidalgo-carcedo, R. Grosse, J. F. Marshall et al., Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells, Nat Cell Biol, vol.9, pp.1392-400, 2007.

D. P. White, P. T. Caswell, and J. C. Norman, alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration, J Cell Biol, vol.177, pp.515-540, 2007.

V. Olaku, A. Matzke, C. Mitchell, S. Hasenauer, A. Sakkaravarthi et al., Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 mice, Mol Biol Cell, vol.22, pp.2777-86, 2011.

E. E. Gardiner, D. Souza, and S. E. , A mitogenic action for fibrinogen mediated through intercellular adhesion molecule-1, J Biol Chem, vol.272, pp.15474-80, 1997.

J. Albrengues, G. Meneguzzi, and C. Gaggioli, Analysis of Collective Invasion of Carcinoma Cells in a 3D

, Organotypic Model. Methods Mol Biol, vol.961, pp.243-52, 2013.

I. Diboun, L. Wernisch, C. A. Orengo, and M. Koltzenburg, Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma, BMC Genomics, vol.7, p.252, 2006.

J. Albrengues, I. Bourget, C. Pons, V. Butet, P. Hofman et al., LIF mediates proinvasive activation of stromal fibroblasts in cancer, Cell Rep, vol.7, pp.1664-1678, 2014.

J. Albrengues, T. Bertero, E. Grasset, S. Bonan, M. Maiel et al.,

V. , M. G. Feral, C. C. Cristofari, G. Gaggioli, and C. , Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts, Nat Commun, vol.6, p.10204, 2015.

A. Avgustinova, M. Iravani, D. Robertson, A. Fearns, Q. Gao et al., Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness, Nat Commun, vol.7, p.10305, 2016.

F. Balkwill, Cancer and the chemokine network, Nat Rev Cancer, vol.4, pp.540-550, 2004.

Y. Ben-neriah and K. M. , Inflammation meets cancer, with NF-?B as the matchmaker, Nat Immunol, vol.12, pp.715-723, 2011.

N. A. Bhowmick, E. G. Neilson, and H. L. Moses, Stromal fibroblasts in cancer initiation and progression, Nature, vol.432, pp.332-337, 2004.

C. Birchmeier, W. Birchmeier, E. Gherardi, V. Woude, and G. F. , Met, metastasis, motility and more, Nat Rev Mol Cell Biol, vol.4, pp.915-925, 2003.

D. A. Bronzert, P. Pantazis, H. N. Antoniades, A. Kasid, N. Davidson et al., Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines, Proc Natl Acad Sci U S A, vol.84, pp.5763-5767, 1987.

F. Bussolino, D. Renzo, M. F. Ziche, M. Bocchietto, E. Olivero et al., Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth, J Cell Biol, vol.119, pp.629-641, 1992.

F. Calvo and E. Sahai, Cell communication networks in cancer invasion, Curr Opin Cell Biol, vol.23, pp.621-629, 2011.

F. Calvo, N. Ege, A. Grande-garcia, S. Hooper, R. P. Jenkins et al., Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancerassociated fibroblasts, Nat Cell Biol, vol.15, pp.637-646, 2013.

M. D. Castellone, H. Teramoto, B. O. Williams, K. M. Druey, and J. S. Gutkind, Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis, Science, vol.310, pp.1504-1510, 2005.

A. Costa, A. Scholer-dahirel, and F. Mechta-grigoriou, The role of reactive oxygen species and metabolism on cancer cells and their microenvironment, Semin Cancer Biol, vol.25, pp.23-32, 2014.

Y. Crawford, I. Kasman, L. Yu, C. Zhong, X. Wu et al., PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment, Cancer Cell, vol.15, pp.21-34, 2009.

D. Wever, O. Nguyen, Q. Van-hoorde, L. Bracke, M. Bruyneel et al., Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac, FASEB J, vol.18, pp.1016-1018, 2004.

C. Dees, M. Tomcik, K. Palumbo-zerr, A. Distler, C. Beyer et al., JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor ? in systemic sclerosis, Arthritis Rheum, vol.64, pp.3006-3015, 2012.

D. G. Denardo, P. Andreu, and L. M. Coussens, Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity, Cancer Metastasis Rev, vol.29, pp.309-316, 2010.

R. Derynck and Y. E. Zhang, Smad-dependent and Smad-independent pathways in TGF-? family signalling, Nature, vol.425, pp.577-584, 2003.

A. Desmoulière, Factors influencing myofibroblast differentiation during wound healing and fibrosis, Cell Biol Int, vol.19, pp.471-476, 1995.

S. Dupont, L. Morsut, M. Aragona, E. Enzo, S. Giulitti et al., Role of YAP/TAZ in mechanotransduction, Nature, vol.474, pp.179-183, 2011.

H. F. Dvorak, Tumors: wounds that do not heal, N Engl J Med, vol.315, pp.1650-1659, 1986.

I. Eke and N. Cordes, Focal adhesion signaling and therapy resistance in cancer, Semin Cancer Biol, vol.31, pp.65-75, 2015.

B. Elenbaas and R. A. Weinberg, Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation, Exp Cell Res, vol.264, pp.169-184, 2001.

N. Erez, M. Truitt, P. Olson, A. St, and D. Hanahan, Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner, Cancer Cell, vol.17, pp.135-147, 2010.

I. V. Fedorenko, K. Paraiso, and K. Smalley, Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma, Biochem Pharmacol, vol.82, pp.201-209, 2011.

K. T. Flaherty, J. R. Infante, A. Daud, R. Gonzalez, R. F. Kefford et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, vol.367, pp.1694-1703, 2012.

J. Folkman, M. Klagsbrun, J. Sasse, M. Wadzinski, D. Ingber et al., A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane, Am J Pathol, vol.130, pp.393-400, 1988.

C. Gaggioli, S. Hooper, C. Hidalgo-carcedo, R. Grosse, J. F. Marshall et al., Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells, Nat Cell Biol, vol.9, pp.1392-1400, 2007.

I. García-tuñón, M. Ricote, A. Ruiz, B. Fraile, R. Paniagua et al., OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative), Cancer Invest, vol.26, pp.222-229, 2008.

L. E. Gerweck and K. Seetharaman, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer, Cancer Res, vol.56, pp.1194-1198, 1996.

M. M. Gottesman, T. Fojo, and S. E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer, vol.2, pp.48-58, 2002.

S. I. Grivennikov, F. R. Greten, and M. Karin, Immunity, inflammation, and cancer. Cell, vol.140, pp.883-899, 2010.

D. Hanahan and R. A. Weinberg, The hallmarks of cancer. Cell, vol.100, pp.57-70, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

M. Hannink and D. J. Donoghue, Structure and function of plateletderived growth factor (PDGF) and related proteins, Biochim Biophys Acta, vol.989, pp.1-10, 1989.

L. Harrison and K. Blackwell, Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy, Oncologist, vol.9, issue.5, pp.31-40, 2004.

A. N. Hata, M. J. Niederst, H. L. Archibald, M. Gomez-caraballo, F. M. Siddiqui et al., Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nat Med, vol.22, pp.262-269, 2016.

E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, Roles of fibroblast growth factor receptors in carcinogenesis, Mol Cancer Res, vol.8, pp.1439-1452, 2010.

L. A. Hazlehurst and W. S. Dalton, Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies, Cancer Metastasis Rev, vol.20, pp.43-50, 2001.

C. Heldin and B. Westermark, Mechanism of action and in vivo role of platelet-derived growth factor, Physiol Rev, vol.79, pp.1283-1316, 1999.

C. Heldin, K. Rubin, K. Pietras, and A. Ostman, High interstitial fluid pressure-an obstacle in cancer therapy, Nat Rev Cancer, vol.4, pp.806-813, 2004.

E. Hirata, M. R. Girotti, A. Viros, S. Hooper, B. Spencer-dene et al., Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin ?1/FAK signaling, Cancer Cell, vol.27, pp.574-588, 2015.

Q. Huang, F. Li, X. Liu, W. Li, W. Shi et al., Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy, Nat Med, vol.17, pp.860-866, 2011.

R. A. Ignotz and J. Massagué, Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix, J Biol Chem, vol.261, pp.4337-4345, 1986.

J. Iijima, K. Konno, and N. Itano, Inflammatory alterations of the extracellular matrix in the tumor microenvironment, Cancers, vol.3, pp.3189-3205, 2011.

R. Kalluri, Basement membranes: structure, assembly and role in tumour angiogenesis, Nat Rev Cancer, vol.3, pp.422-433, 2003.

R. N. Kaplan, R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent et al., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, vol.438, pp.820-827, 2005.

M. Karin and F. R. Greten, NF-kappaB: linking inflammation and immunity to cancer development and progression, Nat Rev Immunol, vol.5, pp.749-759, 2005.

R. S. Kerbel, Tumor angiogenesis, N Engl J Med, vol.358, pp.2039-2049, 2008.

R. Khokha, A. Murthy, and A. Weiss, Metalloproteinases and their natural inhibitors in inflammation and immunity, Nat Rev Immunol, vol.13, pp.649-665, 2013.

Y. Kojima, A. Acar, E. N. Eaton, K. T. Mellody, C. Scheel et al., , 2010.

, Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts, Proc Natl Acad Sci U S A, vol.107, 20009.

V. Koliaraki, M. Pasparakis, and G. Kollias, IKK? in intestinal mesenchymal cells promotes initiation of colitis-associated cancer, J Exp Med, vol.212, pp.2235-2251, 2015.

E. Lazarides and D. R. Balzer, Specificity of desmin to avian and mammalian muscle cells, Cell, vol.14, pp.429-438, 1978.

A. Leask and D. J. Abraham, TGF-? signaling and the fibrotic response, FASEB J, vol.18, pp.816-827, 2004.

L. A. Liotta and E. C. Kohn, The microenvironment of the tumour-host interface, Nature, vol.411, pp.375-379, 2001.

G. V. Long, U. Trefzer, M. A. Davies, R. F. Kefford, P. A. Ascierto et al., Dabrafenib in patients with Val600Glu or Val600Lys BRAFmutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, Lancet Oncol, vol.13, pp.1087-1095, 2012.

C. D. Madsen, J. T. Pedersen, F. A. Venning, L. B. Singh, E. Moeendarbary et al., Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis, EMBO Rep, vol.16, pp.1394-1408, 2015.

F. Maina and R. Klein, Hepatocyte growth factor, a versatile signal for developing neurons, Nat Neurosci, vol.2, pp.213-217, 1999.

I. Malanchi, A. Santamaria-martínez, E. Susanto, H. Peng, H. Lehr et al., Interactions between cancer stem cells and their niche govern metastatic colonization, Nature, vol.481, pp.85-89, 2012.

K. Matsumoto, K. Matsumoto, T. Nakamura, and R. H. Kramer, Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells, J Biol Chem, vol.269, pp.31807-31813, 1994.

G. Maurer, B. Tarkowski, and M. Baccarini, Raf kinases in cancer-roles and therapeutic opportunities, Oncogene, vol.30, pp.3477-3488, 2011.

M. B. Meads, R. A. Gatenby, and W. S. Dalton, Environment-mediated drug resistance: a major contributor to minimal residual disease, Nat Rev Cancer, vol.9, pp.665-674, 2009.

M. L. Mendillo, S. Santagata, M. Koeva, G. W. Bell, R. Hu et al., HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers, Cell, vol.150, pp.549-562, 2012.

P. Mishra, D. Banerjee, and A. Ben-baruch, Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy, J Leukoc Biol, vol.89, pp.31-39, 2011.

R. Montesano, J. D. Vassalli, A. Baird, R. Guillemin, and L. Orci, Basic fibroblast growth factor induces angiogenesis in vitro, Proc Natl Acad Sci U S A, vol.83, pp.7297-7301, 1986.

C. Mørk and O. W. Deurs-b-van,-petersen, Regulation of vimentin expression in cultured human mammary epithelial cells, Differentiation, vol.43, pp.146-156, 1990.

M. M. Mueller and N. E. Fusenig, Friends or foes-bipolar effects of the tumour stroma in cancer, Nat Rev Cancer, vol.4, pp.839-849, 2004.

H. Multhaupt, B. Leitinger, D. Gullberg, and J. R. Couchman, Extracellular matrix component signaling in cancer, Adv Drug Deliv Rev, vol.97, pp.28-40, 2016.

T. Nakamura, K. Matsumoto, A. Kiritoshi, Y. Tano, and T. Nakamura, Induction of hepatocyte growth factor in fibroblasts by tumorderived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions, Cancer Res, vol.57, pp.3305-3313, 1997.

R. Navab, D. Strumpf, C. To, E. Pasko, K. S. Kim et al., Integrin ?11?1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer, Oncogene, vol.35, pp.1899-1908, 2015.

L. J. Nissen, R. Cao, E. Hedlund, Z. Wang, X. Zhao et al., Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis, J Clin Invest, vol.117, pp.2766-2777, 2007.

D. Öhlund, E. Elyada, and D. Tuveson, Fibroblast heterogeneity in the cancer wound, J Exp Med, vol.211, pp.1503-1523, 2014.

K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. Mcintyre et al., Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science, vol.324, pp.1457-1461, 2009.

A. F. Olumi, G. D. Grossfeld, S. W. Hayward, P. R. Carroll, T. D. Tlsty et al., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium, Cancer Res, vol.59, pp.5002-5011, 1999.

A. Orimo, P. B. Gupta, D. C. Sgroi, F. Arenzana-seisdedos, T. Delaunay et al., Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/ CXCL12 secretion, Cell, vol.121, pp.335-348, 2005.

A. Ostman, The tumor microenvironment controls drug sensitivity, Nat Med, vol.18, pp.1332-1334, 2012.

B. C. Özdemir, T. Pentcheva-hoang, J. L. Carstens, X. Zheng, C. Wu et al., Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival, Cancer Cell, vol.25, pp.719-734, 2014.

S. Paget, The distribution of secondary growths in cancer of the breast, Lancet, vol.133, pp.571-573, 1889.

C. K. Pallangyo, P. K. Ziegler, and F. R. Greten, IKK? acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis, J Exp Med, vol.212, pp.2253-2266, 2015.

K. Paraiso and K. Smalley, Fibroblast-mediated drug resistance in cancer, Biochem Pharmacol, vol.85, pp.1033-1041, 2013.

J. E. Park, M. C. Lenter, R. N. Zimmermann, P. Garin-chesa, L. J. Old et al., Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts, J Biol Chem, vol.274, pp.36505-36512, 1999.

D. Paul, A. Lipton, and I. Klinger, Serum factor requirements of normal and simian virus 40-transformed 3T3 mouse fibroblasts, Proc Natl Acad Sci U S A, vol.68, pp.645-648, 1971.

E. Pikarsky, R. M. Porat, I. Stein, R. Abramovitch, S. Amit et al., NF-kappaB functions as a tumour promoter in inflammation-associated cancer, Nature, vol.431, pp.461-466, 2004.

K. Pietras, T. Sjöblom, K. Rubin, C. Heldin, and A. Östman, PDGF receptors as cancer drug targets, Cancer Cell, vol.3, pp.439-443, 2003.

K. Pietras, T. Sjöblom, K. Rubin, C. Heldin, and A. Östman, PDGF receptors as cancer drug targets, Cancer Cell, vol.3, pp.439-443, 2003.

P. I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng et al., RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.480, pp.387-390, 2011.

P. P. Provenzano, C. Cuevas, A. E. Chang, V. K. Goel, V. Hoff et al., Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma, Cancer Cell, vol.21, pp.418-429, 2012.

W. J. Rettig, P. Garin-chesa, J. H. Healey, S. L. Su, H. L. Ozer et al., Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin, Cancer Res, vol.53, pp.3327-3335, 1993.

A. D. Rhim, P. E. Oberstein, D. H. Thomas, E. T. Mirek, C. F. Palermo et al., Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma, Cancer Cell, vol.25, pp.735-747, 2014.

A. B. Roberts, B. K. Mccune, and M. B. Sporn, TGF-?: regulation of extracellular matrix, Kidney Int, vol.41, pp.557-559, 1992.

V. Sanz-moreno, C. Gaggioli, M. Yeo, J. Albrengues, F. Wallberg et al., ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma, Cancer Cell, vol.20, pp.229-245, 2011.

R. Scherz-shouval, S. Santagata, M. L. Mendillo, L. M. Sholl, I. Ben-aharon et al., The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy, Cell, vol.158, pp.564-578, 2014.

Z. M. Shao, M. Nguyen, and S. H. Barsky, Human breast carcinoma desmoplasia is PDGF initiated, Oncogene, vol.19, pp.4337-4345, 2000.

T. J. Shaw and P. Martin, Wound repair at a glance, J Cell Sci, vol.122, pp.3209-3213, 2009.

M. Shimoda, K. T. Mellody, and A. Orimo, Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression, Semin Cell Dev Biol, vol.21, pp.19-25, 2010.

M. Shimoda, S. Principe, H. W. Jackson, V. Luga, H. Fang et al., Loss of the timp gene family is sufficient for the acquisition of the CAF-like cell state, Nat Cell Biol, vol.16, pp.889-901, 2014.

K. Shimokado, E. W. Raines, D. K. Madtes, T. B. Barrett, E. P. Benditt et al., A significant part of macrophage-derived growth factor consists of at least two forms of PDGF, Cell, vol.43, pp.277-286, 1985.

M. Simian, Y. Hirai, M. Navre, Z. Werb, A. Lochter et al., The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells, Development, vol.128, pp.3117-3131, 2001.

J. A. Sosman, K. B. Kim, L. Schuchter, R. Gonzalez, A. C. Pavlick et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, vol.366, pp.707-714, 2012.

R. Straussman, T. Morikawa, K. Shee, M. Barzily-rokni, Z. R. Qian et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, vol.487, pp.500-504, 2012.

F. Strutz, H. Okada, C. W. Lo, T. Danoff, R. L. Carone et al., Identification and characterization of a fibroblast marker: FSP1, J Cell Biol, vol.130, pp.393-405, 1995.

F. Strutz, M. Zeisberg, B. Hemmerlein, B. Sattler, K. Hummel et al., Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation, Kidney Int, vol.57, pp.1521-1538, 2000.

H. Sugimoto, T. M. Mundel, M. W. Kieran, and R. Kalluri, Identification of fibroblast heterogeneity in the tumor microenvironment, Cancer Biol Ther, vol.5, pp.1640-1646, 2006.

M. L. Taddei, E. Giannoni, G. Comito, and P. Chiarugi, Microenvironment and tumor cell plasticity: an easy way out, Cancer Lett, vol.341, pp.80-96, 2013.

J. P. Thiery, Epithelial-mesenchymal transitions in tumour progression, Nat Rev Cancer, vol.2, pp.442-454, 2002.

J. P. Thiery, H. Acloque, R. Huang, and M. A. Nieto, Epithelialmesenchymal transitions in development and disease, Cell, vol.139, pp.871-890, 2009.

J. J. Tomasek, G. Gabbiani, B. Hinz, C. Chaponnier, and R. A. Brown, Myofibroblasts and mechano-regulation of connective tissue remodelling, Nat Rev Mol Cell Biol, vol.3, pp.349-363, 2002.

A. J. Trimboli, C. Z. Cantemir-stone, F. Li, J. A. Wallace, A. Merchant et al., Pten in stromal fibroblasts suppresses mammary epithelial tumours, Nature, vol.461, pp.1084-1091, 2009.

T. Valencia, J. Y. Kim, S. Abu-baker, J. Moscat-pardos, C. S. Ahn et al., Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis, Cancer Cell, vol.26, pp.121-135, 2014.

. Visser-ke-de, A. Eichten, and L. M. Coussens, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer, vol.6, pp.24-37, 2006.

V. Vukovic and I. F. Tannock, Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan, Br J Cancer, vol.75, pp.1167-1172, 1997.

W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto et al., Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors, Clin Cancer Res, vol.15, pp.6630-6638, 2009.

M. Wartenberg, F. C. Ling, M. Müschen, F. Klein, H. Acker et al., Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species, FASEB J, vol.17, pp.503-505, 2003.

J. P. Webber, L. K. Spary, A. J. Sanders, R. Chowdhury, W. G. Jiang et al., Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes, Oncogene, vol.34, pp.290-302, 2015.

W. R. Wilson and M. P. Hay, Targeting hypoxia in cancer therapy, Nat Rev Cancer, vol.11, pp.393-410, 2011.

T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton et al., Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, vol.487, pp.505-509, 2012.

B. S. Wiseman and Z. Werb, Stromal effects on mammary gland development and breast cancer, Science, vol.296, pp.1046-1049, 2002.

K. Wolf, Y. I. Wu, Y. Liu, J. Geiger, E. Tam et al., Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion, Nat Cell Biol, vol.9, pp.893-904, 2007.

X. Wu, X. Chen, Q. Zhou, P. Li, B. Yu et al., Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer, Cancer Lett, vol.335, pp.128-135, 2013.

M. Wysoczynski, K. Miekus, K. Jankowski, J. Wanzeck, S. Bertolone et al., Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas, Cancer Res, vol.67, pp.2131-2140, 2007.

R. L. Yauch, S. E. Gould, S. J. Scales, T. Tang, H. Tian et al., A paracrine requirement for hedgehog signalling in cancer, Nature, vol.455, pp.406-410, 2008.

C. Zeltz and D. Gullberg, The integrin-collagen connection-a glue for tissue repair?, J Cell Sci, vol.129, pp.1284-1284, 2016.